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1. AIMS OF THE STUDY 
 
 
Malignant melanoma is an aggressive cancer form with few treatment options and poor 
survival for patients with advanced disease. Increasing knowledge about molecular changes 
leading to development and progression of melanoma has identified the PI3K/Akt and 
MAPK/ERK1/2 pathways as frequently deregulated mediators of the malignant phenotype. 
Although considerable effort is made to therapeutically target these pathways, desired 
clinical results are yet to be obtained. For this reason there is still a need for more in depth 
dissection of these pathways and identification of novel downstream targets, which could 
hopefully lead to improvement of diagnostic methods and design of new and more efficient 
therapeutic strategies. With this in mind the aims of the present study were to: 
 
1.  Investigate activation status of the PI3K/Akt pathway in melanoma specimens and verify 
its significance in relation to clinicopathological parameters and patient outcome. 
 
2.  Identify and characterize new downstream targets of the PI3K/Akt and MAPK/ERK1/2 
pathways involved in development and progression of melanoma. 
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3. INTRODUCTION 
 
3.1. Cancer 
 
Cancer is thought to arise through clonal expansion of a single cell that has initially acquired 
heritable changes in its DNA. Further accumulation of genetic alterations provides progeny 
cells with selective growth advantages leading to an increase in cell number ultimately 
giving rise to a tumor (1;2). Genetic abnormalities found in cancer include point mutations, 
gene deletions, amplifications, translocations, inversions or duplications and loss of whole 
chromosomes. Additionally, epigenetic mechanisms like hypermethylation, acetylation and 
genomic imprinting also play a central role in development and progression of cancer. 
Common for all these genetic alterations is that they affect two general classes of genes: 
proto-oncogenes and tumor suppressor genes. Activated oncogenes promote proliferation 
and survival while tumor suppressor genes negatively regulate these processes. DNA repair 
or stability genes are a third class of genes altered in cancer. This group is essential for 
maintenance of genome integrity by keeping genetic alterations in the cell to a minimum 
(3;4). In addition to loss of growth control and resistance to apoptosis (programmed cell 
death), cancer cells acquire a variety of special characteristics which define the malignant 
phenotype (hallmarks of cancer), including an extended or indefinite replicative potential 
(replicative immortality), genomic instability, ability to attract or create blood supply 
(angiogenesis), ability to invade the surrounding tissue and ability to survive and proliferate 
in an ectopic environment forming metastasis (Figure 1)(5).   
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Figure 1. Cellular transformation and the main steps in the metastatic process. Clonal   
expansion of genetically altered cell generates new subclones, which accumulate additional 
genetic changes providing them with growth advantage, ultimately leading to formation of a 
primary tumor mass. Further acquisition of malignant features allows tumor cells to fulfill the 
metastatic process. Adapted by permission from Macmillan Publishers  Ltd : ref. (6), © 2003  
 
3.2. Cell cycle 
 
The basic function of the cell cycle is to accurately duplicate DNA and segregate the copies 
into two genetically identical daughter cells. The cell cycle consists of four phases: the S 
phase when DNA replication (synthesis) occurs, the M (mitosis) phase when identical 
chromosome copies are distributed to two new daughter cells and the two gap phases, G1 
and G2, in which the cells are allowed to grow and prepare for the upcoming events of S 
and M, respectively (7). Progression through the G1 phase is highly dependent on 
extracellular signals, stimulating the cells to overcome the so called “restriction point” in 
late G1 (8). After the restriction point, the cells become independent of external mitogenic 
stimuli and can complete the cell cycle autonomously.  
  
Transition through the cell cycle is driven by activated cyclin-dependent kinases (CDKs) 
and their activating cyclin subunits (Figure 2). CDK/cyclin complexes phosphorylate and 
inactivate the retinoblastoma protein (pRb) (9). When pRb is in a hypophosphorylated 
(active) state, it binds E2F transcription factors, thereby preventing expression of genes 
essential for progression from G1 into the S phase (10-12). Phosphorylation (inactivation) of 
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pRb liberates E2F, thus allowing cell cycle progression to occur. CDK activity is regulated 
by two families of inhibitors, INK4 and Cip/Kip (13). INK4 proteins, including p16INK4A, 
p15INK4B, p18INK4C and p14INK4D/ARF specifically bind and inhibit CDK4 and CDK6.  
p14INK4D/ARF also binds directly to MDM2, resulting in stabilization of the tumor suppressor 
protein p53 (14). p53 has an important function in maintaining the integrity of the genome 
by inducing cell-cycle arrest or programmed cell death following DNA damage. The 
Cip/Kip family, composed of p21Cip1/WAF1,  p27Kip1 and p57Kip2 proteins, binds to and inhibit 
the activation of CDK/cyclin complexes (15). 
 
Most human cancers have abrogations in genes that directly or indirectly regulate the cell 
cycle. The most frequently occurring are mutations in RB and TP53 genes as well as 
inactivation of p16INK4A, p15INK4B and p27Kip1 proteins (16;17).  
 
 
 
         Figure 2. Regulation of the mammalian cell cycle, with emphasis on G1-S transition. 
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3.3. Apoptosis 
 
Cells can, upon receiving proper signals, activate intracellular death programs which in a 
sequence of controlled steps leads to locally and temporally defined self-destruction (18;19). 
Programmed cell death has a large biological importance, contributing to homeostasis, 
development, differentiation, regulation and function of the immune system and elimination 
of abnormal, misplaced and  nonfunctional cells (20). One form of programmed cell death is 
termed apoptosis, characterized morphologically by cell shrinkage, chromatin condensation, 
nuclear fragmentation,  membrane blebbing and disassembly into membrane-enclosed 
vesicles followed  by engulfment by resident phagocytes (in vivo) (19;21).  Apoptosis is 
triggered by various stimuli from outside or inside the cell, e.g. by developmental death 
signals or irreparable DNA damage caused by treatment with cytotoxic drugs or irradiation. 
 
The molecular execution of apoptosis involves activation of members of a family of cystein-
dependent aspartate-specific proteases (caspases) that cleaves substrates after aspartic acid 
(asp) residues (22). Two major apoptotic pathways lead to caspase-activation (Figure 3). 
The extrinsic pathway is initiated through stimulation of transmembrane death receptors by 
ligands such as Fas, TNF- and TRAIL (23). Ligand binding leads to receptor clustering 
and association of the adaptor protein Fas-associated death domain (FADD) and the initiator 
caspases 8 or 10, forming a death-inducing signaling complex (DISC) (24-26). This 
complex brings procaspase molecules in the proximity of one another, facilitating their 
autocatalytic processing and release into the cytoplasm. Here they activate effector caspases 
3, 6, and/or 7, responsible for substrate cleavage and appearance of apoptosis–related 
morphological changes (27). Formation of DISC and activation of caspases can be 
modulated by c-FLICE inhibitory protein (c-FLIP), which can interact with FADD to block 
initiator caspase activation. Additional inhibitory mechanism includes decoy receptors, 
which can block ligand binding or directly abrogate pro-apoptotic receptor stimulation (28). 
 
The intrinsic pathway, also referred to as the mitochondrial pathway, is initiated by release 
of cytochrome c from the mitochondria to the cytoplasm. Released cytochrome c, in turn, 
forms a complex with Apaf-1 and caspase 9, which subsequently activates caspase 3. The 
release of cytochrome c is regulated by Bcl-2 proteins, a family of proteins including both 
pro-apoptotic (Bax, Bim, Bad, Bak, Bid, Bcl-XS, Noxa, Puma) and anti-apoptotic members 
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(Bcl-2, Bcl-XL, Mcl-1) (29). The Bcl-2 proteins are regulated mainly through dimerization, 
translocation and phosphorylation (30).  
 
Considerable crosstalk exists between the extrinsic and intrinsic pathways. Thus, caspase 8 
can cleave Bid to tBid, which acts as a signal on the membrane of mitochondria to facilitate 
release of cytochrome c (31). Deregulation of the apoptotic process contributes to tumor 
initiation as well as progression and treatment resistance (32;33).  Tumors often become 
resistant to apoptosis by overexpressing members of the Bcl-2 family of pro-survival 
proteins. In addition, loss of p53 regulated pro-apoptotic genes (e.g., Bax, Noxa, Puma, Bid, 
CD95, APAF-1, DR5, p53AIP) are often observed (34;35) . 
 
 
 
     Figure 3. The extrinsic and intrinsic apoptosis signaling pathways. 
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3.3.1. Anoikis 
 
In most non-transformed cell types, adhesion to extracellular matrix (ECM) is required for 
cellular survival, and disruption of such interaction leads to a specific type of apoptosis 
known as anoikis (Greek for homelessness) (36) In vivo, anoikis prevents detached cells 
from reattaching to new matrices and growing dysplastically. During normal skin renewal, 
keratinocytes undergo anoikis as they loose anchorage to the substratum and eventually are 
shed from the skin (37). In contrast to normal cells, most tumor cells become anoikis 
resistant, making the cells able to leave the primary tumor and subsequently metastasize 
(38). 
 
Anchorage of cells to components of the ECM like fibronectin, collagens, and laminin is 
mainly mediated by integrins, which are transmembrane cell surface receptors. Integrins 
mediate their signals via integrin-associated non-receptor kinases of which focal adhesion-
kinase (FAK) and integrin-linked kinase (ILK) are the best characterized (39). Upon 
integrin ligation, the integrin/FAK signaling complex activates several survival signaling 
pathways inside the cells, including the phosphoinositide-3 kinase (PI3K)/Akt and the 
p42/p44 mitogen-activated protein kinase/extracellular signal-regulated kinases 1/2 
(MAPK/ERK1/2) pathways (40;41). 
 
Anoikis is essentially an apoptotic process and its execution involves both caspases and 
proteins of the Bcl-2 family (42;43). Loss of ECM contact leads to increased accumulation 
of pro-apoptotic Bim due to inhibition of the PI3K/Akt and MAPK/ERK1/2 pathways 
which under normal conditions phosphorylate Bim marking it for proteasome-dependent 
degradation (44). Bim is usually sequestered in the dynein complex, but upon loss of 
integrin engagement it translocates to the mitochondria and interacts with Bcl-XL, 
neutralizing its pro-survival function (45). Thus, constitutively active survival pathways or 
changed pattern of integrin expression makes cancers usually resistant to anoikis. 
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3.4. Cell signaling  
 
Normal cellular homeostasis is dependent on the ability of cells to perceive and correctly 
respond to their microenvironment. Extracellular and intracellular signals are converted to 
an adequate cellular response like cell division, cell cycle arrest or apoptosis through 
complex networks of signaling cascades. Many extracellular signals are transmitted to the 
cells via cell surface receptors. Ligand binding to receptors usually leads to conformational 
changes and phosphorylation of downstream effectors.  
.  
3.4.1. The PI3K/Akt pathway
 
The PI3K/Akt pathway regulates a number of cellular processes, including metabolism, 
growth, proliferation, apoptosis and cell migration (Figure 4) (46).   
PI3Ks are a family of intracellular lipid kinases divided into three major classes (I, II and 
III) according to their structure and substrate specificity. Class I PI3Ks are coupled to 
external stimuli and transmit signals from receptor tyrosine kinases (RTK), integrins and G-
protein coupled receptors. In addition, PI3Ks are also activated by intracellular proteins 
such as PKC, Rac, Rho and Src (47). PI3K catalyzes phosphorylation of inositol-containing 
lipids, known as phosphatidylinositols (PtdIns). Its primary in vivo substrate is 
phosphatidylinositol-4, 5-bisphosphate (PIP2) which is converted to phosphatidylinositol-3, 
4, 5-trisphosphate (PIP3), an important second messenger molecule. PIP3 serves as a 
docking site for subsets of proteins containing pleckstrin homology domains which are 
recruited to the plasma membrane and activated. 
 
 Among major downstream targets of PI3K is the serine/threonine kinase Akt (PKB). 
Translocation of Akt to the membrane brings it close to upstream regulatory kinases such as 
the phosphoinositide dependent kinase 1 (PDK1) that phosphorylates Akt on Thr 308, which 
is necessary for Akt activation. However, maximal activation requires additional 
phosphorylation at Ser473 by the rapamycin-insensitive mTOR complex (mTORC2) (48). 
Activated Akt has been demonstrated to phosphorylate pro-apoptotic Bad leading to its 
degradation as well as caspase 9, which inhibits its catalytic activity, thereby protecting the 
cells from apoptosis. Furthermore, Akt can influence cell survival by indirectly effecting 
nuclear factor of B (NF-B), a central regulator of cell death. Activation of Akt promotes 
multiple effects on cell cycle regulation through phosphorylation and inactivation of the cell 
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cycle regulators, p27Kip1 and p21Cip1/WAF1 and by preventing degradation of cyclin D1 
through inactivation of glycogen synthase kinase 3 (GSK-3) (49-51). 
 
The PI3K/Akt pathway is negatively regulated by the tumor suppressor protein PTEN 
(Phosphatase and tensin homologue deleted on chromosome 10) (52). PTEN is as a dual 
specificity lipid and protein phosphatase which dephosphorylates PIP3. Cells lacking PTEN 
have elevated levels of PIP3 and phosphorylated Akt, making the PI3K/Akt pathway 
constitutively active. PTEN has also been demonstrated to associate with p53 and increase 
its protein levels and activity (53). Furthermore, PTEN is suggested to restrain cell 
migration, an effect dependent on its protein phosphatase activity (54). Most recently, it has 
been shown that PTEN can regulate the c-Jun-N-terminal Kinase (JNK)/stress-activated 
protein kinase (SAPK) pathway in an Akt-independent manner (55). 
 
 
 
  Figure 4. The PI3K/Akt pathway. 
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3.4.2. MAPK pathways
 
Activated cell surface receptors can transmit signals through engagement and activation of 
the MAPK family of protein serine/threonine kinases. The major MAPK pathways include 
the MAPK/ERK1/2, JNK/SAPK and p38-MAPK pathways (Figure 5). Each of these 
pathways is a signaling cascade consisting of a MAPK kinase kinase (MAPKKK or 
MEKK), a MAPK kinase (MAPKK or MEK) and a MAP kinase (MAPK), all activated by 
phosphorylation. 
 
 
 
    Figure 5.  Major MAPK signaling cascades in mammalian cells.  
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3.4.2.1. The MAPK/ERK1/2 pathway 
 
 
The MAPK/ERK1/2 cascade is comprised of Raf, MEK1/2 and ERK1/2 kinases (Figure 6). 
Activation of RTK leads to binding of adaptor molecules containing SH2 domains like Grb2 
and Shc  linking the receptors to a proline-rich region of the guanine nucleotide exchange 
protein SOS (son of sevenless), which stimulates the exchange of GDP for GTP on the Ras 
protein (56). In its GTP-bound state, Ras binds to Raf, bringing it to the plasma membrane 
where its protein kinase activity is increased and downstream kinase cascade is activated 
(57-59). 
 
There are three known mammalian Raf isoforms; A-Raf, B-Raf and C-Raf/(Raf-1), 
translated from distinct genes on different chromosomes with tissue-specific expression and 
subcellular localization (60). Mutations increasing the catalytic activity of the Raf proteins 
have been identified in a number of human tumors. However, mutations in B-Raf occur 
most frequently (61). Raf phosphorylates and activates serine/threonine protein kinases 
MEK1 and MEK2 who subsequently phosphorylate ERK1 and ERK2 on tyrosine/threonine 
residues (62-64). In addition, Raf has been shown to interact with other targets including 
cell cycle regulators (e.g., pRb, Cdc25), apoptosis modulators (e.g., Bcl-2 proteins), 
apoptosis signal-regulating kinase 1 (ASK1) and translation regulators (e.g., eEF-1A), 
suggesting that Raf can modulate cellular processes through MEK1/2/ERK1/2 independent 
mechanisms (65-69). 
 
Activated ERK1/2 phosphorylates numerous substrates in all cellular compartments thereby 
regulating proliferation, differentiation and cell survival. By activating the transcription 
factors AP-1 and ETS, ERK1/2 has been shown to regulate cyclin D1 transcription (70;71). 
Furthermore, physical interaction of CDK2 with ERK1/2 leads to nuclear translocation of 
CDK2, facilitating G1/S transition (72). ERK1/2 has also been shown to phosphorylate and 
modulate p27Kip1, promoting its degradation, which again results in release of active 
CDK2/cyclin E complex and entry into the S-phase (73).  
 
Cellular response to ERK1/2 activation is determined by duration, magnitude and 
subcellular localization of activated ERK1/2 (74). In some cell types sustained activation of 
ERK1/2 is required to induce proliferation while others require only transient activation (75-
77). Furthermore, while moderate levels of ERK1/2 activity have been shown to induce 
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expression of cyclin D1 and cyclin E leading to accumulation of active CDK complexes, 
high levels of ERK1/2 activity influence the CDK inhibitor p21Cip1/WAF1 by transcriptional as 
well as post-translational mechanisms, reducing CDK activity and inducing G1 arrest (78). 
 
 
 
 
Figure 6. The MAPK/ERK1/2 pathway. 
 
The MAPK/ERK1/2 pathway may either enhance or decrease sensitivity to apoptosis 
depending on the stimuli and cell type (79;80). Phosphorylation of Bad by ERK1/2 
  18    
facilitates its binding to 14-3-3-protein, thereby suppressing its pro-apoptotic activity. 
Phosphorylation of Bim, on the other hand, promotes its degradation opposing apoptosis. 
Furthermore, ERK1/2 can increase expression of several pro-survival Bcl-2 proteins, 
including Bcl-2, Bcl-XL and Mcl-1 (81). By inducing MDM2 transcription and thereby p53 
degradation, ERK1/2 can also regulate p53 mediated apoptosis (82).  
 
MAPK/ERK1/2 signaling depends on phosphorylation on both tyrosine and threonine 
residues on ERK1/2, and removing phosphate from either site will ultimately lead to their 
inactivation. Such dephosphorylation is performed by a family of dual specificity 
phosphatases known as MAPK phosphatases (MKPs) (83). Serum and growth factors 
induce expression of certain MKPs, which in some cases contain ERK1/2-sensitive 
promotor elements, indicating that induction of MKPs may create a negative feedback 
mechanism, limiting the time course of ERK1/2 activation. 
 
3.4.2.2. The JNK / SAPK and p38-MAPK pathways
 
 
When exposed to stress, including UV irradiation, osmotic stress, protein synthesis 
inhibitors or inflammatory cytokines, cells can activate the stress-activated protein kinases 
JNK/SAPK and/or p38-MAPK (Figure 5). As ERK1/2, also JNK/SAPK and p38-MAPK are 
activated by MAPKKs through phosphorylation on tyrosine and threonine residues. While 
MKK4 and MKK7 phosphorylate JNK/SAPK, p38-MAPK is phosphorylated by MKK3 and 
MKK6 (84). 
 
A major downstream JNK/SAPK target is the transcription factor activator protein-1 (AP1), 
which is composed of Fos and Jun family members. Phosphorylation of the c-jun 
transcription factor by JNK/SAPK, leads to increased expression of numerous genes with 
AP1 sites in their promoters (85). Among other JNK/SAPK targets are the transcription 
factors ATF2, Elk1, c-myc and  p53, all positive regulators of the transcription factor c-fos, 
further increasing the AP1 level (86). 
Through phosphorylation, activated p38-MAPK regulates p53 and activating transcription 
factor 2 (ATF2), as well as protein kinases, including MAPK-activated kinase 2 (MK2) and 
mitogen-and stress-activated protein kinase 1(MSK1) (87). 
  19    
 Previously it has been anticipated that the MAPK/ERK1/2 signaling pathway mediates cell 
proliferation and survival because of its response to mitotic signals and proliferative 
cytokines, whereas activated JNK/SAPK and p38-MAPK have been suggested to play a role 
in apoptosis. However, also JNK/SAPK and p38-MAPK can regulate diverse cellular 
responses including cell cycle progression, survival and differentiation, depending on the 
stimuli and the strength and duration of their activation.  In addition, recent studies have 
shown that MAPKKKs, believed to specifically activate the JNK/SAPK and p38-MAPK 
signaling pathways, also can activate MEK1/2,  suggesting that different MAPK pathways 
affect each other through cross-talk reactions and feedback mechanisms (88). 
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3.5. IGFBP-3 
 
Among receptors known to activate the PI3K/Akt and MAPK/ERK1/2 pathways is insulin-
like growth factor 1 receptor (IGF-1R). It is activated by IGF-1 and by the related growth 
factor IGF-2, leading to phosphorylation of downstream adaptor proteins belonging to the 
insulin receptor substrate (IRS) family or src homologous and collagen (SHC) proteins (89). 
The activity of IGF-1R is regulated by the availability of its ligands. In serum and 
extracellular fluids, IGFs associate with IGF binding proteins (IGFBPs) which comprise a 
family of six related secreted proteins that specifically bind IGFs with high affinity. Of 
these, IGFBP-3 has the highest affinity for IGF-1 and is also the most abundant IGFBP 
family member in the circulation. Binding of IGF-1 to IGFBP-3 sequesters IGF-1 leading to 
prevention of IGF-1-induced IGF-1R autophosphorylation and signaling (90). In contrast, 
binding of IGFBP-3 to extracellular matrix or cell surfaces through the glycosaminoglycan-
binding domain, decreases the affinity of IGFBP-3 for IGF-1, thereby increasing the level of 
free IGF-1 and receptor activation. IGFBP-3 may also enhance IGF-1 activity by slowly 
releasing IGF-1 to its receptor and inhibit IGF-R down-regulation normally caused by 
sustained IGF-1 exposure (91). 
 
Expression of IGFBP-3 is regulated by interleukin-1 (IL-1), tumor necrosis factor-alpha 
(TNF-), transforming growth factor-beta (TGF-ß) and retinoic acid, as well as by IGF-1 
(90). Also hypoxia can induce IGFBP-3 mRNA through p53-independent and dependent 
mechanisms. Moreover, signaling through the PI3K/Akt and MAPK/ERK1/2 pathways has 
been shown to regulate IGFBP-3 expression (92). 
 
IGFBP-3 can influence proliferation, migration, and apoptosis independently of its effects 
on IGF signaling (93). IGFBP-3 can attenuate mitogenic signaling and proliferation by 
activating a phosphotyrosine phosphatase that inhibits IRS-1 and IRS-2 proteins,  
terminating signaling through the PI3K/Akt and MAPK/ERK1/2 pathways (94). In both 
prostate and ovarian carcinoma cells, IGFBP-3 was shown to have IGF-independent 
inhibitory effects on adhesion, migration and invasion (95;96). It has also been 
demonstrated that IGFBP-3 can translocate into the nucleus and interact with nuclear 
receptor retinoid X receptor (RXR) and NR4a1 to induce apoptosis (97;98). IGFBP-3 is also 
a mediator of apoptosis induced by TGF- and TGF- in multiple cell types. The 
multifunctional roles reported for IGFBP-3 are likely to be influenced by posttranslational 
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modifications, susceptibility to proteases and/or interactions with several signaling 
pathways (99-102). IGFBP-3 is secreted as a phosphoprotein and shown to be 
phosphorylated in vitro by casein kinase II (CKII), cAMP-dependent protein kinase (PKA), 
double-stranded DNA-dependent protein kinase (DNA-PK) as well as ERK1/2 (103). 
Phosphorylation of IGFBP-3 can affect its nuclear import, binding affinity to other proteins, 
and growth inhibitory actions.  
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3.6. FABP7 
 
 
Fatty acid binding proteins (FABPs) are a family of small (15kDa) highly conserved 
proteins that bind long-chain fatty acids and other hydrophobic ligands and thus have a role 
in lipid metabolism. This family is divided into two subgroups, one cytoplasmic (FABPc) 
and one associated with the plasma membrane (FABPm). There are nine tissue-specific 
FABPs (FABP1 - FABP9) found in liver, intestine, heart, testis, adipose tissue, epidermis as 
well as brain and peripheral nervous system  (104). FABP7, also known as brain lipid 
binding protein (BLBP), is expressed in radial glia cells during development and regulated 
through activation of Notch receptors (105;106). 
 
FABPs expression in a given tissue reflects its lipid-metabolizing capacity. In cells like 
hepatocytes and adipocytes with high lipid biosynthesis and turnover of fatty acids, FABPs  
make up between 1% and 5% of all soluble cytosolic proteins (104). FABPs facilitate 
uptake of fatty acids by binding and minimizing the amount of unbound fatty acid in the 
cells thereby creating a concentration gradient. In addition, binding of fatty acids to FABPs 
increases their solubility and reduces potentially harmful excess of amphipathic molecules 
inside the cells (107). 
 
FABPs have also been implicated in gene regulation, cell signaling, growth and 
differentiation and are considered as co-activators in PPAR-mediated gene control since 
they can enter the nucleus and target fatty acids to transcription factors (108). By binding 
mitogens and interacting with other proteins, FABPs are thought to contribute to growth and 
differentiation (109).  
 
There is evidence that different FABPs are involved in cancer development and progression. 
A decrease in FABP1 level was observed with progression of colon cancer while loss of 
FABP4 expression is reported in bladder cancer (110;111). In contrast, both FABP1 and 
FABP2 are over-expressed in prostate and breast cancers (112;113). In prostate cancer 
FABP5 expression was associated with poor prognosis (114). Moreover, high FABP7 
expression in glioblastomas is related to poor prognosis (115). FABP7 expression has also 
been reported in melanomas, where it is suggested to play a role in cell proliferation and 
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invasion (116). Recently, FABP7 was detected in patients with the basal like subtype of  
breast cancer and  associated with better clinical outcome (117).  
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3.7. Melanoma  
 
Malignant melanoma (melanoma) is derived from the pigment-producing cells termed 
melanocytes. These cells originate in the neural crest (ectoderm) and during embryogenesis 
migrate to the basal layer of the epidermis, uveal tract in the eye and mucous membranes. 
Although cutaneous melanoma is most frequently occurring, cancer can develop in all 
melanocyte containing tissues (118). 
 
3.7.1. Epidemiology and risk factors 
 
Even though melanoma accounts for only 4% of all dermatological cancers, it is highly 
aggressive and responsible for 80% of total deaths related to skin cancer (119). Each year 
approximately 160 000 new cases of melanoma are diagnosed and about 40 000 deaths are 
caused by this disease worldwide (120) (Figure 7). The highest incidence rates are found in 
Australia, New Zealand, North America and northern countries of Europe. With 1 200 new 
cases diagnosed each year, Norway is among the European countries with the highest 
incidence (121). Major factors that indicate a high risk of melanoma include a family history 
of multiple benign or atypical nevi,  fair skin and excessive exposure to UV radiation,  
resulting in burning, mainly during childhood (122). 
 
 Figure 7. a) Age-standardized incidence and mortality rate for melanoma in Norway b) 5- 
year survival rate of patients diagnosed from 1997 to 2001 (raw data obtained from Cancer 
Registry of Norway 2007) 
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3.7.2. Melanoma stages and prognostic factors
 
The diagnosis of melanoma is based on several criteria and the “ABCDE" method of 
identification is widely used (123). This method analyzes five clinical characteristics 
including asymmetry (A), border irregularity (B), color variation (C), a diameter of 6 mm or 
more (D) and evolving (E), meaning changes in the lesion over time [4]. However, some 
melanomas lack all or most of the features defined in the "ABCDE" criteria (124). Further 
examination of the skin biopsy is, therefore, needed to determine whether the mole is benign 
or malignant.  
 
Once a diagnosis has been made, the stage of the disease can be assessed by determining 
Breslow’s thickness of the primary lesion, ulceration and the presence of metastases 
(125;126). Tumors are grouped into the following main stages: Stage 0 melanoma, also 
called melanoma in situ, involves the epidermis but has not reached the underlying dermis. 
Stage I and II include tumors less than 1 mm thick and between 1 and 4 mm, respectively, 
and with no evidence of regional lymph node or distant metastases. Stage III melanomas 
have spread to regional lymph nodes while stage IV tumors are associated with metastases 
to distant sites in the body. The most common sites of metastases are skin, subcutaneous 
tissues, distant lymph nodes as well as lungs, liver and brain. The most powerful 
independent prognostic factors for stage I and II cutaneous melanoma are tumor thickness 
and ulceration.  
 
If detected early, stage I melanoma is curable with surgery and 5-years survival rate is 
above 90% (127). Patients with advanced (stage III) and distant metastatic (stage IV) 
disease at presentation can expect 5-year survival rates of 60%, and 5-15%, respectively. 
The median survival of stage IV patients is 6-9 months (128;129). 
  
3.7.3. Melanoma subtypes 
 
Based on the combination of clinical and pathological features, melanomas can be divided 
into four main clinical subgroups. These include superficial spreading melanoma which 
account for 70% of all cases, nodular melanomas (15%), acral lentiginous melanoma (10%) 
and lentigo maligna melanoma (5%) (130). Lentigo maligna melanoma is more prevalent on 
chronically sun-damaged skin of head, neck, and arms in elderly. Acral lentiginous 
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melanoma is the most common form of melanoma in non-Caucasians, developing on palms, 
soles, mucous membranes and underneath or near fingernails and toenails (131). With the 
exception of nodular melanomas, which are more aggressive, the growth patterns of the 
other subtypes are characterized by an in situ growth phase (radial growth) that may last for 
months before dermal invasion occurs.  
 
3.7.4. Melanoma progression
 
The skin is composed of three primary layers: epidermis, dermis and subcutis. Melanocytes 
reside in the basal layer of the epidermis, forming an epidermal melanin unit in contact with 
basal keratinocytes.  This unit is characterized by a life-long stable ratio of 1:36 between 
melanocytes and keratinocytes (132). Homeostasis is maintained by keratinocytes regulating 
melanocyte division by growth factors and cell-cell adhesion molecules. This fine balance is 
disturbed during transformation into a nevus or a melanoma. According to Clark's model, 
melanomas develop and progress in a sequence of steps from normal melanocytes to 
metastatic melanoma via common acquired and congenital nevi without dysplasia (benign 
nevi), dysplastic nevi, radial-growth phase (RGP) melanoma, vertical-growth phase (VGP) 
melanoma and metastatic melanoma (Figure 8). However, RGP or VGP melanomas may 
also arise directly from melanocytes without a previous benign or borderline melanocytic 
lesion. Approximately 70% of the melanomas appear on clinically normal skin whereas 
30% develops in association with pre-existing nevi. Transition from RGP to VGP is 
considered to be a critical step in progression since VGP melanomas are able to grow 
anchorage-independently and have acquired metastatic competence that is  not present in 
RGP lesions (133). 
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         Figure 8. Development of melanoma. Adapted from ref (134).  
 
3.7.5. Molecular profile of melanoma 
 
Approximately 5% to 10% of all cutaneous melanomas are hereditary. In 20% to 40% of 
these families, germline mutations in the CDKN2A gene residing on chromosome fragment 
9p21 have been identified (135). The CDKN2A gene encodes two different proteins: 
p16INK4A encoded by exons 1a, 2, and 3 and p14INK4D/ARF encoded by alternative splicing of 
an alternative exon 1b to exon 2. Both proteins have a tumor-suppressor function, regulating 
cell proliferation by inhibition of CDKs or by enhancing the effect of p53. In addition, 2% 
of the families harbor mutations in the CDK4 gene affecting the p16INK4A binding site 
(136;137).  
 
Hyperactivation of the MAPK/ERK1/2 pathway has a central role in the tumorigenesis of 
melanomas (138). The most common alterations leading to this hyperactivation are gain-of-
function mutations in NRAS or B-Raf. While NRAS is mutated in between 4% and 50% of 
melanomas, 25% to 80% harbor B-Raf mutations (139). The most common aberration in the 
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NRAS gene is a substitution of glutamine to either lysine (Q61K) or arginine (Q61R) at 
codon 61, while mutations in B-Raf most often involve valine to glutamate substitution at 
residue 600 (V600E) (140;141). However,  B-Raf is also mutated in between 20% and 80% 
of benign nevi which typically remain in a growth-arrested state for decades and only rarely 
progress into melanoma (140;142). Whereas B-RafV600E stimulates melanoma cell 
proliferation, sustained B-RafV600E expression in normal melanocytes leads to cell cycle 
arrest accompanied by induction of p16INK4A, resulting in senescence (143-145). Induction 
of senescence by B-RafV600E suggests that additional genetic or epigenetic changes are 
required to induce full melanocyte transformation (146;147). 
 
The PI3K/Akt signaling pathway is another important survival pathway in melanoma. PI3K 
mutations and activation of Akt are detected in 3% and 60% of melanomas, respectively, 
whereas loss of PTEN function occurs in between 5% and 20% of late-stage tumors (148-
150). In melanoma subtypes where B-Raf and NRAS mutations are rare, including 
melanomas on mucosal membranes, acral skin, and skin with chronic sun-induced damage, 
amplifications and activating mutations of C-KIT have been observed (151). C-KIT is a 
RTK upstream of the PI3K/Akt and MAPK/ERK1/2 pathways.  
 
The microphtalmia-associated transcriptional factor (MITF) is a basic helix–loop–helix 
leucine zipper transcription factor that regulates development, differentiation and 
maintenance of melanocytes, but is also essential for melanoma cell proliferation and 
survival (152). Recently it was shown that MITF is amplified in a small subset (10–16%) of 
metastatic melanomas in which B-Raf is mutated (153). 
 
During progression from RGP to VGP, melanoma cells alter the expression pattern of cell 
surface cadherins responsible for cell-cell adhesion. Loss of E-cadherin and subsequent 
breakdown of melanocyte-keratinocyte interactions followed by upregulation of N-cadherin 
is characteristic for melanoma cells (154;155). Furthermore, loss of E-cadherin expression 
can also lead to increased signaling through the Wnt/-catenin signaling pathway. Changes 
in components of the Wnt/-catenin signaling pathway, promoting cell proliferation through 
regulation of genes like c-Myc, MITF, CCND1 (cyclin D1) and MMP-7, have been reported 
in many cancers, including melanoma (156). Progression from RGP to VGP is also 
associated with increased expression of V3 integrin (157). Integrins mediate contact 
between cells and components of the extracellular matrix like fibronectin, collagens and 
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laminin. Integrin  V3 can also stimulate the motility of melanoma cells by inducing 
expression of matrix metalloproteinase 2, an enzyme that degrades collagen in the basement 
membrane (158). 
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4. SUMMARY OF THE PAPERS 
 
Paper I. Expression of activated Akt and PTEN in malignant melanomas: relationship with 
clinical outcome
In this study, we analyzed the protein expression of activated Akt (pAkt) and PTEN in a 
panel of 41 benign nevi, 162 primary (103 superficial spreading and 59 nodular) and 71 
metastatic melanomas using immunohistochemistry and correlated the expression level with 
clinicopathological parameters. Cytoplasmic and/or nuclear expression of pAkt was seen in 
54% of the nevi, 71% of the primary tumors and 72% of the metastases. Cytoplasmic PTEN 
staining was observed in 88% of the primary tumors and 90% of the metastases whereas no 
immunoreactivity was detected in benign nevi.   
We found a significant correlation between PTEN and cytoplasmic pAkt expression 
(P<0.001) in primary tumors. In superficial spreading melanomas, cytoplasmic pAkt 
expression showed a positive association with cyclin A (P=0.038), which was not the case 
for nodular melanomas (P=0.22). Furthermore, we did not find any association between 
disease-free and overall survival and cytoplasmic pAkt and PTEN expression when 
performing Kaplan-Meier analysis. However, complete lack of nuclear pAkt expression was 
a predictor of shorter disease-free survival (P=0.025) for patients with superficial spreading 
melanomas.  In conclusion, our results suggest that the PI3K/Akt pathway is activated in a 
relative high number of melanomas without loss of PTEN. The current model of a simple 
linear relationship between PTEN and activation status of Akt  can not explain these results. 
These two factors do not appear to be valuable prognostic markers in malignant melanoma. 
 
 
Paper II: The fatty acid protein 7 (FABP7) is involved in proliferation and invasion of 
melanoma cells 
Using gene expression profiling (AffymetrixTM) we  identified FABP7 as one of the most 
differentially expressed genes in melanoma cells cultivated as multicellular aggregates 
(spheroids) treated with the PKC activator PMA and/or the MEK1 inhibitor PD98059 (159). 
FABP7 mRNA and protein levels were down-regulated after treatment of melanoma cell 
lines with PMA and/or PD98059. In vitro, siRNA mediated down-regulation of FABP7 
protein led to decreased cell proliferation and invasion, but did not affect apoptosis. 
Immunohistochemical staining of 11 benign nevi, 149 primary (93 superficial spreading  
and 56 nodular) and 68 metastatic melanomas reveald that 91% of the nevi, 71% of the 
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primary and 70% of the metastases expressed FABP7 in the cytoplasm and/or the nucleus In 
superficial spreading melanomas, FABP7 expression was associated with tumor thickness 
(P = 0.021). Furthermore, there was a trend for an association between FABP7 expression 
and Ki-67 score (P = 0.070) and shorter relapse-free survival (P = 0.069) in this group of 
patients. Taken together, these results suggest that FABP7 is a downstream target of both 
PKC and the MAPK/ERK1/2 pathway in melanoma cells. FABP7 does not seem to be 
involved in apoptosis in melanoma cells, but rather contributes to proliferation and invasion.  
 
Paper III: Biological effects induced by insulin-like growth factor binding protein 3 
(IGFBP-3) in malignant melanoma. 
In this paper we have characterized expression, function and regulation of IGFBP-3 in 
melanomas as well as evaluated its potential as a biomarker. IGFBP-3 showed variable 
expression in human melanoma cell lines and no clear differences were observed between 
cell lines originating from primary tumors vs. metastases.   
Reintroduction of the protein in cells naturally lacking IGFBP-3 led to induction of 
apoptosis.  In cell lines constitutively expressing IGFBP-3, siRNA mediated silencing led to 
a cell line dependent decrease in proliferation, but had no effect on apoptosis and invasion. 
In patient material, we found that IGFBP-3 was not expressed in benign nevi while a slight 
increase in protein expression was seen in primary and metastatic tumors.  However, overall 
expression of the protein was low and we found no correlation between disease stage and 
circulating levels of IGFBP-3 in serum. For this reason, we concluded that IGFBP-3 has 
limited potential as a predictive biomarker in melanoma. We detected IGFBP-3 promoter 
methylation in both melanoma cell lines and patient material suggesting that IGFBP-3 is 
regulated by epigenetic silencing. In addition, we found that both the PI3K/Akt and the 
MAPK/ERK1/2 pathways can regulate IGFBP-3 expression level. In summary, our findings 
suggest that IGFBP-3 can have several roles in melanomas, influencing both apoptosis and 
proliferation. Development of resistance to the antiproliferative effects of IGFBP-3 may be 
an important step in progression of this disease.  
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5. METHODOLOGICAL CONSIDERATIONS 
 
5.1. Tissue Material 
 
The tissue material used in this thesis was selected from a malignant melanoma archive at 
the Norwegian Radium Hospital and is derived from patients that underwent surgery since 
the 1980s. Research on this material has been approved by The Regional Committee for 
Medical Research Ethics in Norway.  
 
5.2. In vitro Cell Cultures 
 
Use of in vitro cell cultures for studies of basic biological mechanisms in both normal and 
cancer cells has many advantages. However, it is also important to recognize the limitation 
of these models when interpreting the results. Continuous cell cultures are poorly 
differentiated, and lose many of the phenotypic characteristics of the original cell type in
vivo. Heterogeneity in growth rate and the capacity to differentiate within the population can 
produce variability and there is evidence that cell lines at high passage numbers show 
changes in morphology, growth rates as well as  response to stimuli and protein expression, 
compared to lower passage cells (160;161). Lack of standardized culturing conditions can 
result in different phenotypes being expressed by the same cell lines, making the 
interlaboratory comparability of in vitro results difficult. To minimize these variations, in
vitro cell cultures used in this study were routinely sustained in RPMI 1640 medium 
supplemented with 5%-10% fetal calf serum (FCS) and experiments were performed under 
minimal changes to these conditions.  Furthermore, we have avoided using cell lines that 
have been kept in culture too long.   
 
5.3. Measurements of cell viability and apoptosis
 
In this thesis we aimed to study biological processes affected by particular signaling 
pathways or treatments applied, and for this reason we have used several methods to 
measure cell viability, proliferation and apoptosis. Cell viability was measured using the 
MTS-assay (Cell Titer Aqueous Non-Radioactive Cell Proliferation Assay (Promega, 
Madison, WI) which is a colorimetric method for detecting the amount of living cells. The 
colored end product is linearly correlated to the dehydrogenase activity in metabolically 
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active cells. However, this method can poorly distinguish between cell cycle arrest and 
apoptosis. Therefore, we have also used the [3H]-thymidine incorporation assay for DNA 
synthesis to measure proliferation rates.  
 
The TUNEL (terminal deoxynucleotidyl transferase end labeling) method was used to 
evaluate the degree of apoptosis. This method is based on detection of internucleosomal 
DNA fragmentation, a typical event during apoptosis. The formation of DNA strand breaks 
is detected by enzymatic labeling of the 3’-OH termini with modified nucleotides. However, 
in some cases, internucleosomal DNA degradation does not occur during apoptosis, making 
the number of DNA strand breaks inadequate to distinguish apoptotic cells by this method 
(162;163). Likewise, DNA fragmentation can also stop after the initial cleavage of DNA to 
fragments of 50 to 300 kb, resulting in low frequency of DNA strand breaks (164). In 
addition, TUNEL will stain necrotic cells to some degree due to extensive DNA 
degradation. Permeabilization and the subsequent cell washing after ethanol fixation, allows 
extraction of small pieces of fragmented DNA, leading to a diminished number of DNA 
strand breaks. 
5.4. Protein Detection  
 
We have used both immunohistochemistry and Western blot analysis to study expression of 
proteins of interest in patient material and cell lines, respectively. Immunohistochemistry 
identify proteins by a microscopically evaluation of tissue sections. This method provides 
information about the localization and distribution of a particular protein in the entire tissue 
section as well as in single cells. Specificity and amount of antibody used, pretreatment such 
as fixation and antigen retrieval and the use of different controls, in addition to subjectivity 
of interpretation of staining patterns and different scoring systems may influence the results 
(165). All antibodies used in this thesis were commercially available. For antibodies that 
could be used in both applications, the specificity was tested by western blot analysis to 
confirm that the band of predicted size is detected. The immunohistochemical method was 
optimized for each antibody and all series included positive control samples which were 
either a tissue known to contain the antigen under study or cell lines examined by western 
blot analysis. Negative controls included substitution of the monoclonal primary antibody 
with mouse myeloma protein of the same subclass and concentration and replacement of the 
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polyclonal antibody with normal rabbit IgG of the same concentration as the polyclonal 
antibody In addition, when possible, we used cell lines transfected with siRNA, targeting 
the protein of interest, as negative controls. All controls gave satisfactory results. 
 
5.5. Cell Migration Assay  
 
In papers II and III we used Matrigel invasion chambers (BD Biosciences, San Jose, CA) to 
study cell invasion. Important considerations when performing these experiments had to be 
taken into account, including how to quantify the number of migrating cells and which cells 
to include. Moreover, we had to consider whether the treatment applied had additional 
effects on the tumor cells which could affect the measurement. Such experiments are 
technically demanding and had to be repeated many times to obtain satisfactory 
reproducibility.  
One of the critical factors is thickness of the Matrigel in each well. Even though we used 
pre-coated commercial chambers, we did experience variation between batches. For this 
reason, the results from the experiments were presented as percentage compared to the 
adequate controls. Since the WM35 cell line is poorly aggressive, relatively few cells 
invaded through the Matrigel after 24 hours of incubation. Due to this, we chose to extend 
the incubation time to 48 hours. In paper II we quantified invading cells at the bottom 
surface of the chamber membranes by fixing, staining with hematoxylin and counting as 
recommended by the supplier. However, in this case it was difficult to exclude effects of 
cell viability on the results. In order to avoid similar problems in paper III, we chose to 
incorporate [3H]-thymidine in the cells prior to seeding and quantified the number of cells 
in both compartments (upper and lower side of the membrane) separately using a 
scintillation counter. By using the ratio between cells numbers in both compartments we 
could more accurately calculate the percentage of invading cells and eliminate the impact of 
seeding and viability variability.  
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5.6. Qunatitative Real-Time RT-PCR
 
When performing quantitative PCR experiments, it is of importance to minimize errors that 
can be introduced due to differences in starting amount of RNA as well as differences in 
efficiency of cDNA synthesis or PCR amplification. This and sample variation is corrected 
for by the use of control genes, which are often referred to as housekeeping genes. 
However, the expression level of these genes may vary among tissues or cells and may 
change under certain circumstances. Thus, the selection of housekeeping genes is critical for 
gene expression studies. In our studies we have used the beta-glucuronidase (GUS) gene to 
normalize the mRNA expression level of genes of interest. GUS was chosen based on our 
pilot studies using TaqMan® Low Density Array Human Endogenous Control Panel 
(Applied Biosystems) which contains commonly used housekeeping genes that exhibit 
minimal differential expression across 16 different tissues. GUS was shown to have stable 
transcript level under the various experimental conditions. 
 
5.7. siRNA transfection 
 
Through this thesis we utilized siRNA to transiently down-regulate proteins in order to 
study their contribution to tumorigenesis of melanomas. All siRNA oligonucleotide 
duplexes (Stealth RNAi) were obtained from Invitrogen (Invitrogen, San Diego, CA). 
Negative controls included siRNA with the same nucleotide composition as the target 
siRNA, but lacking significant sequence homology to the genome (scrambled siRNA). To 
verify siRNA mediated knock-down of proteins, Western blot analysis was performed for 
each experiment.  
The use of siRNA can induce cellular stress response pathways such as the interferon 
response. This can result in growth inhibition and cellular toxicity, making it difficult to 
assess whether the observed cellular effects are due to non-specific stress responses or to 
loss of function of a target gene. All our transfections were optimized to achieve the greatest 
amount of target-specific knock-down of expression, as well as a low rate of toxicity in cells 
transfected with scrambled siRNA by using the lowest effective concentrations. However, 
the possibility that the observed phenotype might be due to knock-down of other genes 
caused by nucleotide sequence similarity between the siRNA molecule and short motifs in 
their mRNAs can not be completely excluded 
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6. RESULTS AND DISCUSSION 
 
6.1. Activation status of the PI3K/Akt pathway and its association with clinical 
outcome in melanoma patients 
 
During the last decade the PI3K/Akt and MAPK/ERK1/2 pathways have emerged as central 
signaling cascades deregulated in melanoma, contributing to both development and 
progression of the disease (166). In this context our project has focused on validation of 
these pathways in clinical settings and identification and characterization of new 
downstream targets.  
 
The first evidence of deregulated PI3K/Akt pathway came in 1988, when Parmiter et al. 
reported loss of chromosome 10, harboring the PTEN gene, in melanoma samples (167). 
However, before 2005, few studies had evaluated the role of altered PTEN expression or 
activation of Akt in relation to clinical outcome for melanoma patients. Thus, in paper I we 
analyzed the expression of PTEN and activation status of Akt in melanocytic tissues using 
immunohistochemistry and correlated our findings to clinical parameters.  
 
We observed variable degree of PTEN cytoplasmic staining in 88% of primary and 90% of 
metastatic melanomas, suggesting that complete lack of PTEN protein expression is not a 
frequent event in melanomas. Notably, however, approximately 30% of both primary and 
metastatic tumors expressed PTEN in less than 50% of the cells. In support of our results, 
Zhou et al. reported lack of PTEN in 15% (5/34) and low expression in 50% (17/34) of the 
tested melanomas. In addition, others have reported lack of or decreased PTEN protein 
expression in up to 30-40% of melanomas (168-172). Even though mutations in PTEN are 
not frequent in melanomas (173;174), it is assumed that PTEN can be disrupted in as many 
as 40–50% of sporadic melanomas by other mechanisms, such as epigenetic silencing (175), 
altered subcellular localization (169) or ubiquitination (176). 
 
Although the frequency of PTEN loss in our primary melanoma samples was in accordance 
with other observations, total lack of immunoreactivity in benign nevi was highly surprising 
and in contrast to previous reports (171). However, loss of PTEN protein expression in nevi 
has also been reported in a study by Packer et al. (172) where 59% nevi showed little or no 
PTEN staining while it was detected in 67% of primary and 37% of metastatic melanomas. 
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Thus, based solely on these immunohistochemical results, it is difficult to draw conclusions 
on the role of PTEN in benign nevi. 
 
Lack of immunoreactivity does not necessarily reflect absence of protein, but can rather be 
due to methodological factors like suboptimal tissue preparation and inadequate epitope 
unmasking. In addition, the use of different antibodies is likely to result in different PTEN 
staining which could partially explain the discrepancy in reported results. Interestingly, 
while our paper was under revision, Pallares et al. published results describing PTEN 
staining pattern in a panel of endometrial carcinomas, using four different anti-PTEN 
commercial antibodies, including the polyclonal antibody from Zymed used in our study 
(177). In addition, they also correlated the results to the presence of abnormalities in the 
PTEN gene and expression of phosphorylated Akt (pAkt). In accordance with our 
observations, they reported cytoplasmic PTEN staining using the Zymed antibody. 
However, a wide variability in the results was obtained using the different antibodies. 
Furthermore, the Zymed PTEN antibody showed no correlation with pAkt immunostaining. 
Surprisingly, when correlated with the presence of molecular alterations in the PTEN gene 
(mutations, loss of heterozygosity, or promoter hypermethylation), the mean H-score was 
higher in tumors with molecular alterations of PTEN as compared to those having wild type 
PTEN.  
 
Although previous studies have suggested that loss of PTEN expression is associated with 
poor prognosis in other tumor types (178-180), we did not find any association with clinical 
parameters. This is in agreement with the study by Whiteman et al. (169), who failed to 
demonstrate any association between PTEN expression and clinical features such as Clark's 
level and Breslow thickness. Furthermore, Mikhail et al. (170), found no correlation 
between PTEN expression and disease-free and overall survival in melanoma patients. 
Together, these results suggest that the tumor expression level of PTEN by it self has 
limited utility in predicting clinical outcome for melanoma patients. Nevertheless, the 
importance of PTEN has been confirmed by many functional studies and recently Dankort 
et al. showed that PTEN loss and B-RafV600E cooperate to promote metastasis in melanoma 
(181). In their mouse model, expression of B-RafV600E at physiological levels, in 
combination with PTEN loss, led to tumor development. 
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When examining Akt activation in our melanoma panel, we observed variable degree of 
cytoplasmic and nuclear pAkt staining in 44% of the benign nevi and in 68% of the 
melanomas. This was in accordance with a study by Dhawan et al. who reported little pAkt 
immunoreactivity in benign nevi but high pAkt levels in up to 66% of dysplastic nevi and 
melanomas (182). Similarly, Stahl et al. showed that selective activation of the Akt3 
isoform, caused by increased gene copy number and decreased PTEN protein activity, 
occurs in 43–60% of sporadic melanomas (149). In their study, weak or moderate pAkt 
staining was detected in 100% of common nevi, while strong staining was observed in 12% 
of dysplastic nevi, 53% of primary and 67% of metastatic melanomas. Furthermore, 
simultaneously with us, Dai et al. reported strong pAkt expression in 17%, 43%, 49% and 
77% of normal nevi, dysplastic nevi, primary and metastatic melanomas, respectively (183). 
Collectively, these studies have confirmed that activation of the PI3K/Akt pathway is a 
frequent event in melanomas.  
 
Dai et al. also found that pAkt expression was inversely correlated with both overall and 
disease-free survival, and was a poor prognostic factor for patients with melanomas less 
than 1.5 mm in thickness. We did not observe any associations with disease-free or overall 
survival in our cohort. This discrepancy might be due to different evaluation of 
immunostaining, definition of low vs. high Akt activation, subclassification of our tumors as 
well as subdividing into groups based on tumor thickness. However, we did observe a 
positive correlation between cytoplasmic pAkt and cyclin A, in accordance with a previous 
report by Shen et al. (184). Since cyclin A expression has been related both to proliferation 
as well as tumor thickness and clinical outcome in melanomas (185), activation of Akt 
might indirectly contribute to disease progression by increasing proliferation. 
 
Surprisingly, in our study, lack of pAkt expression in the nucleus was a predictor of shorter 
disease-free survival in patients with superficial spreading melanoma. Recently, similar 
results were obtained by Jovanovic et al. (186). In further support of our findings, other 
studies have reported that nuclear pAkt expression is correlated with better prognosis in 
lung, endometrial and renal cell carcinoma (187-189). In prostate cancer, Page et al. 
reported that nuclear Akt1 and Akt2 expression correlated with parameters of favorable 
outcome (190). Although Akt3 is the predominant isoform activated in melanomas, specific 
effects of the other isoforms are not well studied. The antibody used in our study is reactive 
to Akt1 phospho-epitopes, but cross-reacts also with the homologous phospho-epitopes in 
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Akt2 and Akt3. For this reason, our results might reflect the possibility that each Akt 
isoform have a different role and that their subcellular localization may be important in 
determining cellular effects. 
 
In contrast to previous reports, we detected a positive correlation between cytoplasmic pAkt 
and PTEN expression (191;192). However, similar results have been reported in a large 
cohort of breast and ovarian carcinomas, suggesting that a common linear model of Akt 
activation upon PTEN inactivation is oversimplified (193;194). In support of this view, 
Gewinner et al. recently identified inositol polyphosphate 4-phosphatase type II (INPP4B) 
as a new tumor-suppressor in human epithelial cells that decreases Akt activation by 
hydrolyzing phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) (195). 
 
In our study, we observed a positive association between Akt and ERK1/2 activations. Since 
these pathways are often activated in the same cells, the observed positive correlation might 
reflect their simultaneous parallel activation. Still, there is also evidence that the PI3K/Akt 
and MAPK/ERK1/2 cascades are interconnected (196-198). The PI3K/Akt signaling 
pathway has in several cases been reported to inhibit, rather than increase, ERK1/2 
activation. In normal cells, pAkt has been shown to phosphorylate B-Raf to decrease its 
activity (199;200). Recently, Cheung et al. suggested that B-RafV600E and Akt3 
cooperatively promote melanoma development (201). They showed that activating B-
RafV600E mutation initially promotes nevi development, but the resulting high, intense 
activation of the MAPK/ERK1/2 pathway inhibits further tumor progression. For further 
progression to occur, activation of Akt3 is required to phosphorylate and inhibit B-RafV600E, 
lowering the levels of the MAPK/ERK1/2 pathway activity to levels promoting, rather than 
retarding, melanocytic cell growth and transformation.  
 
6.2. Identification and characterization of novel targets of the PI3K/Akt and 
MAPK/ERK1/2 pathways  
 
Previously, we and others showed that the PI3K/Akt and MAPK/ERK1/2 pathways play a 
role in preventing anoikis and facilitating anchorage-independent growth, thereby being  
involved in metastasis (159;202-204). Our results showed that in the early stage melanoma 
cell line, WM35, which undergoes spontaneous cell death when cultivated as three-
dimentional multicellular aggregates (spheroids) in suspension, activation of  PKC confers 
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anoikis resistance partially through the MAPK/ERK1/2 pathway (159). Interestingly, in 
these cells, cultivation as spheroids also increased the PTEN protein level, suggesting 
involvement of the PI3K/Akt pathway (unpublished results). Furthermore, in addition to 
increasing the degree of anoikis in these cells, inhibition of the MAPK/ERK1/2 pathway 
using the MEK1 inhibitor PD98059 led to further increase in PTEN protein level ((159) and 
unpublished results).  
 
In our further studies we exploited the spheroid model to study how these pathways 
contribute to survival and apoptosis/anoikis of melanoma cells and to identify and 
characterize novel downstream targets. We used high throughput gene expression profiling 
(AffymetrixTM) to identify differentially expressed genes in untreated WM35 cells cultured 
as monolayer and spheroids, as well as in spheroids treated with the PKC activator PMA 
and/or the MEK1 inhibitor PD98059. The data analysis of the microarray experiments 
revealed that FABP7 and IGFBP-3 were among the most significantly differentially 
expressed genes (unpublished results). For this reason we have in paper II and III further 
characterized their role in melanoma biology. 
 
6.2.1. FABP7 
 
Our data analysis showed that both PKC activation and MEK1 inhibition, previously 
reported to exert opposite effect on anchorage-independent survival (159), led to down-
regulation of FABP7 mRNA in WM35 spheroids, arguing against its involvement in 
promotion of anchorage-independent survival. Activation of PKC resulted in down-
regulation of FABP7 even in the presence of activated ERK1/2, suggesting that this effect is 
mediated independently of the MAPK/ERK1/2 pathway. Previously it has been shown that 
both PKC and the MAPK/ERK1/2 pathway can regulate the activity of the peroxisome 
proliferator-activated receptors / (PPAR /) (205-207). Furthermore, binding of PPAR 
/ to the response element PPRE can regulate several proteins of the FABP family, making 
it likely that also FABP7 might be regulated through this mechanism. (208;209). Even 
though we have not investigated a possible regulation of FABP7 by the PI3K/Akt pathway 
in paper II, our recent preliminary experiments have  shown that treatment of WM35 cells 
with the PI3K inhibitor LY294002 leads to a decrease in the FABP7 protein expression 
(unpublished results). Interestingly, FABP7 has been identified as a direct target of Notch 
signaling in radial glial cells, which share many biological properties with melanocytes due 
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to their common origin (210). In melanoma cells, hyperactivation of the PI3K/Akt pathway 
was shown to up-regulate Notch expression (211). Thus, regulation of FABP7 via Notch 
and the PI3K/Akt pathway might also be possible in melanoma, but remains to be further 
investigated. 
 
To clarify the role of FABP7 in the biology of melanomas, we transiently down-regulated 
its expression in the primary WM35 and the metastatic WM239 cell lines. This down-
regulation significantly inhibited proliferation in both cell lines. However, we did not 
observe any effect on apoptosis. This, together with our observations in WM35 spheroids, 
showing that FABP7 did not contribute to anchorage-independent survival, suggests that 
FABP7 rather contributes to melanoma proliferation. In support of these results, Goto et al. 
showed that proliferation of melanoma cell lines is reduced upon down-regulation of 
FABP7 without affecting apoptosis (116). Furthermore, we showed that FABP7 down-
regulation reduced the invasive potential, which is also in agreement with Goto et al. (116). 
Previously, Mita et al. reported that introduction of FABP7 into a FABP7-negative 
malignant glioma cell line enhanced its migratory properties while the opposite was 
observed after reduction of its expression in FABP7-positive cells (212). Altogether, our 
results have placed FABP7 as a possible mediator of proliferative and invasive effects 
downstream of PKC and the MAPK/ERK1/2 pathway in melanoma cells in vitro. 
Furthermore, regulation of FABP7 expression by the PI3K/Akt pathway is likely to occur as 
well.  
 
When investigating FABP7 protein expression in vivo, we surprisingly observed that benign 
nevi had the highest protein expression, while it was slightly lower in primary and 
metastatic melanomas. This is in accordance with the study by de Wit et al. who, found that 
the FABP7 was down-regulated in melanoma tissue compared to nevi (213). However, our 
analysis of the clinical data revealed that in superficial spreading melanoma, high FABP7 
expression is positively associated with Ki-67 expression and thicker primary tumors. 
Although, not reaching significance, probably due to limited sample size, an association 
between FABP7 expression and shorter disease-free survival was observed in this group of 
patients as well, suggesting that FABP7 may contribute to disease progression by  
increasing cell proliferation in vivo. 
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Taking into consideration both the in vitro results and the correlation of FABP7 expression 
with the disease progression, high expression of FABP7 in nevi compared to melanomas 
seems contradictory. Interestingly, in the study by Goto et al., FABP7 expression decreased 
with disease progression due to genomic instability and LOH of the 6q21–23 chromosome 
region containing the FABP7 gene (214). As cutaneous melanoma progress, genomic 
instability becomes more prominent and LOH becomes more frequent in specific 
chromosome regions (215). Furthermore, the majority of benign nevi are terminal lesions 
that do not progress to melanoma and the molecular events in these cells differ from those in 
melanoma cells. For this reason it is possible that FABP7 have a different role in nevi.  
 
Taken together, our in vitro and in vivo observations support the hypothesis that FABP7 has 
disease promoting features in melanomas. In accordance with this, Goto et al. reported that 
FABP7 expression in melanoma metastasis was associated with poor clinical outcome 
(214). Moreover, a negative association between FABP7 expression and poor prognosis was 
previously observed in glioblastoma patients (115;216). However, FABP7 expression has 
also been found in the mammary gland, but in a mouse breast cancer model its over-
expression inhibited tumour growth (217;218). Recently, Zhang et al. reported that in the 
basal-like subclass of breast cancer, FABP7 expression was associated with better patient 
outcome, suggesting that FABP7 effects are tissue specific (117). 
 
6.2.2. IGFBP-3 
 
As previously described, IGFBP-3 was another gene found to be highly differentially 
expressed in our microarray studies. Data analysis showed that treatment of WM35 
spheroids with the MEK1 inhibitor PD98059 led to decreased IGFBP-3 mRNA levels 
placing it downstream the MAPK/ERK1/2 pathway. Previously, several studies have 
suggested involvement of IGFBP-3 in different cancer types (219-221). However, only one 
study by Xi et al. has described its potential role in melanomas, suggesting that IGFBP-3 
expression may be an important migration and proliferation factor necessary for metastasis 
(222). 
 
Validation of our microarray data revealed that although highly differentially regulated upon 
PD98059 treatment, mRNA and protein levels of IGFBP-3 in WM35 cells were very low. In 
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paper III we indeed showed that IGFBP-3 protein is not ubiquitously expressed in 
melanoma cell lines or in patient material. We found that this lack of constitutive expression 
could partially be explained by promoter methylation and gene silencing of IGFBP-3, as 
previously reported in several other tumor types (223-225). Evidence of promoter 
methylation and gene silencing accompanied with low protein expression, argue against the 
proposed disease promoting role in melanoma. 
 
To clarify these discrepancies, we chose to re-express IGFBP-3 protein in two IGFBP-3 
negative cell lines and transiently down-regulate its expression in two IGFBP-3 positive cell 
lines. We observed that re-expression of IGFBP-3 induced apoptosis, which is in agreement 
with previous studies showing that IGFBP-3 is capable of exerting pro-apoptotic effects 
(226;227). Also, exogenously added IGFBP-3 has been shown to induce apoptosis in 
several cell systems.  However, in our study, exogenously applied IGFBP-3 did not exert 
such effects, suggesting that only intracellular IGFBP-3 has apoptosis-inducing capabilities 
(228;229). In support of our results, intracellular IGFBP-3 has been shown to induce 
apoptosis by several mechanisms including increasing the ratio of pro-apoptotic to anti-
apoptotic proteins or by interacting with these, and by interacting with the retinoid X 
receptor (RXR) and  the orphan nuclear receptor NR4a1 (98;230). Lack of effect by 
exogenously applied IGFBP-3 might suggest that the protein is not internalized by the cells 
used in our study. 
 
In contrast to these observations, transient down-regulation of IGFBP-3 in cell lines with 
high endogenous IGFBP-3 expression led to cell line-dependent effect on proliferation, but 
did not affect apoptosis or invasion. Possibly, in these cell lines, down-regulation of IGFBP-
3 leads to lower recruitment of IGF-1, and thereby reduced receptor activation, ultimately 
leading to decreased proliferation. However, since IGF-1 does not have a predominant role 
in proliferation of metastatic melanoma cells (231) and our findings demonstrate low levels 
of IGF-R1 in these cells, it is likely that the observed IGFBP-3 effects are IGF-1 and IGF-
R1 independent.  Previous studies have suggested that IGF-1 independent actions of IGFBP-
3 might be mediated by its high affinity binding to putative IGFBP-3 cell surface receptors, 
but these have yet to be confirmed (232;233).  
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Taken together, these results suggest that IGFBP-3 can exert opposing cell type specific 
effects. In support of our results, a recent study by Dupart et al. obtained similar results in 
gastrointestinal stromal tumor cell lines (234). In addition, McCaig et al. showed that 
IGFBP-3 normally induced apoptosis in breast Hs578T cancer cells, but this effect was 
reversed in non-IGF-responsive Hs578T cells when plated onto fibronectin (235). 
Furthermore, they showed that IGFBP-3 could have positive or negative effects on growth 
and survival in these cells, depending on the status of cholesterol-stabilized integrin receptor 
complexes (236). 
 
In an attempt to explain different expression patterns and the differences in biological 
effects exerted by IGFBP-3, we further analyzed downstream components of the IGF 
signaling pathway. The results revealed PTEN loss in IGFBP-3 expressing cell lines and 
constitutive activation of the MAPK/ERK1/2 and PI3K/Akt pathways. Treatment of the 
cells with the MEK1 inhibitor PD98059 or the PI3K inhibitor LY294002 led to 
transcriptional down-regulation of IGFBP-3, suggesting that IGFBP-3 can be regulated 
through both the MAPK/ERK1/2 and PI3K/Akt pathways. Furthermore, down-regulation of 
PTEN protein in unmethylated IGFBP-3 negative melanoma cell line with wild type PTEN, 
increased IGFBP-3 protein expression, again suggesting that PTEN can regulate IGFBP-3 
either directly or via the PI3K/Akt pathway. Regulation of IGFBP-3 by the MAPK/ERK1/2 
and PI3K/Akt pathways has previously been shown in other cell types, but appears to be cell 
type specific. Thus, in a study of gastric cancer cell lines, Yi et al. showed that inhibition of 
the PI3K/Akt pathway led to up-regulation rather that down-regulation of IGFBP-3 (237).  
Taken together, these observations made us hypothesize that in melanoma cell lines lacking 
high constitutive activation of the MAPK/ERK1/2 and PI3K/Akt pathways, IGFBP-3 
suppress tumorigenesis by inducing apoptosis. Activation of these pathways during disease 
progression, however, allows cells to escape from the growth-inhibitory effects of IGFBP-3 
and rather utilize it to stimulate growth and proliferation.  
 
The in vitro observations were also confirmed in our in vivo studies. We found that IGFBP-
3 protein is not highly expressed in melanoma biopsies. As seen in vitro, lack of protein 
expression in melanoma biopsies could be explained by methylation of the IGFBP-3 
promoter. Furthermore, a trend towards an inverse association between IGFBP-3 and PTEN 
protein expression was observed in clinical samples, suggesting that regulation via the 
PI3K/Akt signaling pathway might also occur in vivo. Nevertheless, although overall low, 
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IGFBP-3 expression was up-regulated in metastatic lesions (37%) as compared to primary 
melanomas (6%) and benign nevi (0%) which is in agreement with our observations in the 
cell lines and the study by Xi et al. (222). Induction of IGFBP-3 mRNA in response to 
hypoxia in lung carcinoma cells has been shown to be mediated by both p53-independent 
and -dependent mechanisms (238). It is possible that in fast growing metastatic melanoma 
tissues, hypoxic areas occur more frequently than in smaller primary tumors, which could 
partially contribute to induction of IGFBP-3.  
 
While high IGFBP-3 expression has been associated with unfavorable prognosis in breast 
cancer patients (239), elevated serum IGFBP-3 levels were reported to reduce the relative 
risk of developing breast cancer (240). In our study, we did not reveal any differences in 
IGFBP-3 levels in the plasma samples from normal control individuals compared to 
melanoma patients with stage II and IV disease. The fact that in most of the biopsies, 
IGFBP-3 expression was seen in less than 5% of the tumor cells, may explain the lack of 
correlation between tumor progression and IGFBP-3serum levels, implicating that IGFBP-3 
can not be used as a serum marker in patients with melanoma. In support of these results, 
studies in other cancer forms found no predictive value for serum IGFBP-3 levels 
(220;241). Recently Yu et al. showed that IGFBP-3 serum levels in melanoma patients and 
healthy adults were comparable and thus had no clinicopathological relevance (242). 
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7. CONCLUDING REMARKS 
 
 
In this thesis we have focused on studying how the PI3K/Akt and MAPK/ERK1/2 pathways 
contribute to development and progression of melanoma. We confirmed that the PI3K/Akt 
pathway is deregulated in vivo since both loss of PTEN expression and high activation of 
Akt occur in melanoma lesions. The presence of pAkt in benign nevi suggests that 
activation of the PI3K/Akt pathway might be an early event, possibly contributing to tumor 
development.  
In superficial spreading melanomas, activated cytoplasmic Akt is positively associated with 
cyclin A, through which it might influence cell cycle progression. However, nuclear pAkt is 
associated with longer disease-free survival in these patients, suggesting that activated Akt 
exerts different functions in melanomas depending on its localization. Nevertheless, lack of 
a direct association between PTEN expression or Akt activation and patient outcome make 
these factors less useful as prognostic biomarkers.  
 
Furthermore, we have identified two proteins, FABP7 and IGFBP-3, as downstream targets 
of the PI3K/Akt and MAPK/ERK1/2 pathways in melanoma cells. We showed that FABP7 
is involved in proliferation and invasion in vitro. FABP7 is expressed in melanocytic lesions 
and associated with proliferation and tumor thickness in patients with superficial spreading 
tumors, suggesting that for these patients, FABP7 could be a potential target for therapy. 
 
IGFBP-3 can exert dual biological functions in melanomas by either inducing apoptosis in 
early stages of the disease, or positively contributing to proliferation in later stages. During 
disease progression, further accumulation of malignant changes in the cells, including 
increased activation of the PI3K/Akt and MAPK/ERK1/2 pathways, makes cells refractory 
to the inhibiting effects of IGFBP-3 and even able to utilize it to their advantage. IGFBP-3 
increases during melanoma progression, but due to its overall low expression, it has little 
diagnostic value as a biomarker in this cancer type.  
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8. FUTURE PERSPECTIVES 
 
Even though collectively, PTEN deregulation occurs in 30% to 40% of melanomas, the 
frequency of Akt activaton appears to be even higher, suggesting that a linear relationship 
between these events is oversimplified. Identification of INPP4B as a new tumor-
suppressor, whose down-regulation leads to enhanced Akt activation and anchorage-
independent growth, adds new insight into the regulation to this pathway (195). In  the study 
by Gewinner et al.,  deletions of chromosome region 4q31.1-3, harboring the INPP4B gene, 
were detected in 21.6% of the examined melanomas (195). For this reason it is of interest to 
investigate if INPP4B can contribute to regulation of Akt activation in melanoma cells as 
well. Our preliminary data suggests that INPP4B mRNA level is reduced in metastatic 
melanoma cell lines compared to cell lines derived from early lesions, supporting the tumor-
suppressor hypothesis. Interestingly, INPP4B also emerged as one of the up-regulated genes 
in WM35 spheroids compared to monolayer control in our microarray study. Our further 
aim is to analyze INPP4B protein expression both in vitro and in vivo, and to correlate its 
expression to Akt activation. Our preliminary data show that down-regulation of PTEN in 
WM35 cells do not activate Akt significantly, even after stimulation with growth factors. 
We wish to examine if simultaneous down-regulation of both PTEN and INPP4B will 
increase Akt activation and how this will effect anchorage-independent survival and growth.  
 
Several studies have provided evidence that as melanomas progress, there is functional 
redundancy between signaling pathways mediating survival. For this reason, probably only 
simultaneous inhibition of multiple pathways will result in synergistic induction of cell 
death and overcome therapy resistance. Inhibiting MAPK/ERK1/2 in conjunction with the 
PI3K/Akt pathway is likely to synergize at the level of Bcl-2 family proteins to induce 
apoptosis.  Recently, the orphan nuclear receptor NR4a1 (Nur77/TR3) was identified as a 
possible downstream target of both of these pathways (243). Upon receiving a proper 
apoptotic signal, NR4a1 is phosphorylated and translocated from the nucleus to the 
mitochondria, where it interacts with Bcl-2 to trigger apoptosis (244). It has been shown that 
NR4a1 nuclear export requires prolonged MEKK1/JNK/SAPK activation and inhibition of 
Akt activation (245). Our microarray and RT-PCR results showed that NR4a1 is regulated 
by PKC and the MAPK/ERK1/2 pathway in melanoma cells. One previous study have 
suggested that NR4a1 is involved in apoptosis in melanoma cells (246). Interestingly, in 
prostate cancer, IGFBP-3 regulates translocation of NR4a1 to the mitochondria. In this 
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setting, NR4a1 has an important role as a mediator of IGFBP-3 induced apoptosis (98). We 
aim to further investigate the role of NR4a1 in melanoma proliferation and apoptosis in
vitro and in vivo. We also wish to map in detail the signaling pathways involved in 
regulation of NR4a1 expression and translocation.  Since we have shown that IGFBP-3 can 
induce apoptosis in melanoma cells, it will be of interest to examine if NR4a1 is involved in 
this process.  
 
Two compounds shown to induce nuclear export of NR4a1 are anisomycin and CD437 
(243). Anisomycin is an antibiotic which inhibits protein synthesis and activates stress-
activated protein kinases JNK/SAPK and p38-MAPK. CD437 is a synthetic retinoic acid 
with selective apoptotic activity in a large variety of leukemic and solid tumor cells (247). 
Both compounds have been shown to induce apoptosis in melanoma cells, making them 
interesting from a clinical perspective (248;249). We wish to investigate if NR4a1 is 
involved in induction of apoptosis after anisomysin/CD437 treatment and explore which 
signaling pathways are mediating this effect. 
 
 
In order to further study the contribution of the PI3K/Akt and MAPK/ERK1/2 pathways to 
survival of melanoma cells under anchorage-deprived conditions, we have recently 
preformed gene expression profiling of anoikis-sensitive WM35 cells and the anoikis- 
resistant variant WM35sph6, both cultured as monolayer and spheroids (unpublished 
results). WM35sph6 cells represent a subpopulation of WM35 cells selected for ability to 
grow anchorage-independently by repeated prolonged cultivation as spheroids. 
 
Among the genes found to be differentially expressed between these two cell lines was 
IGFBP-7. By high affinity binding to insulin, IGFBP-7 can modify its distribution and 
ability to bind to the receptor, thereby influencing downstream the PI3K/Akt and 
MAPK/ERK1/2 pathways. Previously it has been suggested that IGFBP7 function a as 
tumor-suppressor in colorectal adenocarcinoma (250). More recently, Wajapeyee et al. 
suggested that B-RafV600E expression in primary melanocytic cells leads to synthesis and 
secretion of IGFBP-7, which acts through autocrine/paracrine pathways to inhibit 
MAPK/ERK1/2 signaling and induce senescence and apoptosis, thereby suppressing 
melanoma development (251). The authors also suggested a potential therapeutic 
application of these findings, since treatment of B-RafV600E melanoma cells with 
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recombinant IGFBP-7 was able to trigger apoptosis both in vitro and in vivo. However, the 
role of IGFBP-7 in melanomas is highly debated since a newly published paper by Schrama 
et al. failed to find any correlation between IGFBP-7 expression and B-Raf mutational status 
(252). Our microarray data showed that IGFBP-7 is up-regulated in the anoikis-resistant and 
more aggressive WM35sph6 cells, which argues against its tumor-suppressor role. It will be 
of interest to further characterize the role of IGFBP-7 in melanomas and its possible 
influence on the PI3K/Akt and MAPK/ERK1/2 pathways. 
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Abstract
Background: The molecular mechanisms underlying melanoma tumor development and
progression are still not completely understood. One of the new candidates that emerged from a
recent gene expression profiling study is fatty acid-binding protein 7 (FABP7), involved in lipid
metabolism, gene regulation, cell growth and differentiation.
Methods: We studied the functional role of FABP7 in human melanoma cell lines and using
immunohistochemistry analyzed its expression pattern and clinical role in 11 nevi, 149 primary
melanomas and 68 metastases.
Results: FABP7 mRNA and protein level is down-regulated following treatment of melanoma cell
lines with a PKC activator (PMA) or MEK1 inhibitor (PD98059). Down-regulation of FABP7 using
siRNA decreased cell proliferation and invasion but did not affect apoptosis. In clinical specimens,
FABP7 was expressed in 91% of nevi, 71% of primary melanomas and 70% of metastases, with a
cytoplasmic and/or nuclear localization. FABP7 expression was associated with tumor thickness in
superficial spreading melanoma (P = 0.021). In addition, we observed a trend for an association
between FABP7 expression and Ki-67 score (P = 0.070) and shorter relapse-free survival (P =
0.069) in this group of patients.
Conclusion: Our data suggest that FABP7 can be regulated by PKC and the MAPK/ERK1/2
pathway through independent mechanisms in melanoma cell lines. Furthermore, FABP7 is involved
in cell proliferation and invasion in vitro, and may be associated with tumor progression in
melanoma.
Background
Malignant melanoma is the most lethal skin cancer and
accounts for about 75% of all deaths from skin tumors. In
its early stage, melanomas can be treated surgically, but
once the tumor has progressed, it is difficult to treat and it
does not respond to current therapies. The molecular
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mechanisms underlying melanoma development and
progression are still not completely understood, and
novel diagnostic and prognostic markers, as well as thera-
peutic targets are needed [1].
We have previously reported that phorbol-12-myristate-
13-acetate (PMA), a protein kinase C (PKC) activator,
increases proliferation and promotes anchorage-inde-
pendent survival of melanoma cells cultivated as multicel-
lular aggregates in suspension (spheroids). This protective
action was at least partly mediated through PKC and MEK-
independent activation of the mitogen-activated protein
kinase/extracellular signal-regulated kinases 1/2 (MAPK/
ERK1/2) [2]. In an attempt to identify additional genes
involved in survival and apoptosis of melanoma cells, we
used high throughput gene expression profiling (Affyme-
trix™) to identify differentially expressed genes in
untreated cells cultured as monolayer or spheroids, as
well as in spheroids treated with PMA and/or the MEK1
inhibitor PD98059. The analysis revealed that the fatty
acid-binding protein 7 (FABP7, BLBP or B-FABP) [3,4] was
among the most significantly differentially expressed
genes (unpublished results).
FABP7 belongs to a family of structurally-related proteins
showing tissue-specific patterns of expression. Nine
FABPs (FABP1 – FABP9), expressed in normal liver, intes-
tine, heart, adipose tissue, epidermis, brain, peripheral
nervous system and testis have been identified (reviewed
in [5]). FABP proteins are involved in lipid metabolism,
including uptake and intracellular trafficking of fatty acids
and retinoids. In addition, they play a role in gene regula-
tion, cell signaling, cell growth and differentiation [6].
Several reports have suggested a possible role for the dif-
ferent FABP proteins in cancer biology, linking their levels
with either increasing or decreasing degree of malignancy.
Adamson et al. reported that FABP5 (C-FABP/E-FABP)
protein expression is higher in prostate cancer compared
to prostatic hyperplasia [7]. On the other hand, the FABP1
level decreases with progression of colon cancer [8].
FABP7 is highly expressed in glia cells throughout devel-
opment of the nervous system [4,9] and high FABP7
expression in glioblastomas is related to poor prognosis
[10]. Recently, two studies have addressed FABP7 expres-
sion in surgical specimens from melanoma patients.
While de Wit et al. reported down-regulation of FABP7 in
melanomas compared to nevi, Goto et al. found FABP7 to
be frequently expressed in melanomas, and suggested that
it may play a role in cell proliferation and inva-
sion[11,12].
In the current study we examined the role of FABP7 in
proliferation, apoptosis and invasion of melanoma cells
grown in vitro and studied possible regulation mecha-
nisms of this protein. In addition, we examined the
expression of FABP7 protein in clinical melanoma speci-
mens and assessed the relationship between FABP7
expression pattern and known prognostic variables, cell
cycle factors and disease progression. We report that
FABP7 is regulated via PKC and the MAPK/ERK1/2 signal-
ing pathway in melanoma cells in vitro and promotes pro-
liferation and invasion. Moreover, FABP7 expression is
associated with tumor thickness and proliferation in
melanoma biopsies.
Methods
Cell lines and Growth Conditions
The Wistar Melanoma (WM) cell lines were kindly pro-
vided by Dr. Meenhard Herlyn (Wistar Institute, Philadel-
phia, PA) and have been described in detail elsewhere
[13].
The MeWo cell line was derived from a lymph node
metastasis [14]. The cell lines FEMX-I and LOX were estab-
lished from metastatic lymph node biopsies obtained
from melanoma patients treated at the Rikshospitalet-
Radiumhospitalet Medical Center [15]. The cells were rou-
tinely cultured in RPMI 1640 medium (BioWhittaker
Europe, Verviers, Belgium) supplemented with 5% fetal
calf serum (FCS) (Biochrom, KG, Berlin, Germany). Phor-
bol-12-myristate-13-acetate (PMA) was from Sigma-
Aldrich (St. Louis, MO), whereas the MEK1 inhibitor,
PD98059, was from Cell Signaling Technology (Beverly,
MA). Multi-cellular aggregates (spheroids) were prepared
as previously described [16]. Briefly, 24-well plates were
coated with 1% Seaplaque agarose (BioWhittaker Molec-
ular Application, Rockland, ME) and tumor cells (2 × 105
cells in 1 ml complete medium) were plated on top of the
solidified agarose. For thymidine incorporation assay,
5000 cells per well were plated in 96-well polyhema
(Sigma-Aldrich)-coated U-bottom plates. For treatment of
spheroid cultures, PMA was added when plating in sus-
pension, whereas the inhibitors in combination experi-
ments were added 45 min prior to plating as spheroids.
Gene expression analysis
WM35 cells were grown as spheroids for 24 hrs in the
presence of PMA and PD98059, alone and in combina-
tion. Total RNA was extracted using the TRIZOL reagent
(Invitrogen, Carlsbad, CA). Gene expression profiling was
performed using Affymetrix U133 Plus 2.0 arrays (Affyme-
trix, Santa Clara, CA). For microarray hybridization, the
protocol described in the Affymetrix GeneChip eukaryotic
one-cycle target preparation protocol, using 5 g of total
RNA, was followed. Analysis of the data was performed by
Genolyze Ltd. (Turku, Finland) using statistical software R
version 2.3.0. and package collection Bioconductor ver-
sion 1.8. Statistical significance was assessed using p-value
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from two-tailed two sample t-test. P-values are replaced
with q-values to control the False Discovery Rate.
Quantitative real time RT-PCR analysis
The high capacity cDNA reverse transcription kit (Applied
Biosystems, Foster city, CA) was used to reverse-transcribe
total RNA (0.8 g) in a 20 l reaction mixture using ran-
dom primers. The real-time PCR analyses were performed
using TaqMan Fast Universal PCR Master Mix (2×) and
TaqMan Gene Expression Assay (HS00361426-ml FABP7,
HS99999908-ml GUS, Applied Biosystems). A total of 0.5
l cDNA was used in 25 l PCR mixtures with 900 nM of
each primer and 250 nM TaqMan probe. The reactions
were carried out in a 7900 HT Fast Real Time PCR system
(Applied Biosystems) with the following program: 95°C
for 20 sec. followed by 40 cycles of 95°C for 1 sec., 60°C
for 20 sec. Each sample was run in triplicate. The FABP7
relative mRNA expression level was normalized with
respect to the beta-glucuronidase (GUS) gene, which had
stable transcript levels under these experimental condi-
tions. The mean from three independent experiments was
calculated.
Immunoblotting
Cells were lysed in ice-cold NP-40 lysis buffer (1% NP-40,
10% glycerol, 20 mM Tris-HCl, pH 7.5, 137 mM NaCl,
100 mM sodium vanadate, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 0.02 mg/ml each of aprotinin, leupep-
tin, and pepstatin, and 10 l/ml phosphatase inhibitor
cocktail I and II (Sigma-Aldrich)). Protein quantitation
was done by Bradford analysis and 25 g protein/lane was
resolved by SDS polyacrylamide gel electrophoresis.
Transfer and hybridization were as described in [17]. To
ensure even loading, filters were stained with naphthol-
blue black (Sigma-Aldrich) and re-stained with -tubulin.
The antibodies against FABP7 and -tubulin were from
R&D Systems (Minneapolis, MN) and Calbiochem (San
Diego, CA), respectively. HRP-conjugated anti-mouse IgG
secondary antibody was from Promega (Madison, WI)
and HRP-conjugated anti-goat secondary antibody was
from DAKO A/S (Glostrup, Denmark).
Small interfering RNA transfection
Fifty thousand cells per well were seeded in 24-well plates
for 24 hrs prior to transfection with 50 nM siRNA target-
ing FABP7 (OligioID: HSS103516; Catalog# 1299003) or
negative control siRNA duplexes (Catalog#12935-300)
using Lipofectamine™ RNAiMAX transfection reagent (all
reagents and siRNA were from Invitrogen). Cells were
detached 48 hours after transfection and plated into agar-
ose-coated 24-well plates as spheroids for an additional
72 hrs for assessment of apoptosis, seeded into 96-well
polyhema-coated U-bottom plates for the proliferation
assay and plated in BioCoat Matrigel invasion chambers.
Proliferation assay
Five thousand cells per well were seeded in 96-well poly-
hema-coated U-bottom plates for spheroids and in 96-
well flat-bottom plates for monolayer cells and cultured
for 72 hrs, the last 24 hrs with the addition of 3.7 × 104 Bq
[3H]Thymidine (ARC, St.Louis, MO) Thereafter, the cells
were harvested using a Filtermate Harvester (Packard
Instrument Co. Meriden, CT). [3H]Thymidine incorpora-
tion was assessed in a Packard Microplate Scintillation
Counter. Proliferation assays were measured in triplicate.
The experiment was repeated at least three times.
Flow cytometric analysis of apoptosis
The adherent cells were harvested by Trypsin and together
with detached cells fixated in 100% cold methanol. Fixed
cells were washed with PBS, incubated for 30 min at 37°C
in 50 l terminal transferase (TdT) solution containing 5
units TdT (Roche, Basel, Switzerland), 10 l 5× reaction
buffer (supplied with TdT), 1.5 mM CoCl2, 0.5 nmol
labeled biotin-16-dUTP, 0.1 mM dithiothreitol and dis-
tilled water. The cells were subsequently washed once in
PBS containing 0.1% Triton X-100 and incubated in 50 l
1:50 streptavidin-FITC (Amersham, Buckinghamshire,
UK) in PBS (0.1% Triton X-100) and 3% skimmed dry
milk for 45 min at room temperature. After washing in
PBS (0.1% Triton X-100) the pellet was resuspended in
PBS (0.1% Triton X-100) containing 2 g/ml Hoechst
33258 to a final concentration of 1 × 106 cells/ml and
incubated for 30 min at 4°C. Data acquisition and analy-
sis were performed on Becton Dickinson LARII (Becton
Dickinson immunocytometry systems, San Jose, CA)
using Multifit software (FACSDiVa House inc., Tonsham,
ME).
Matrigel invasion assay
WM35 and WM239 cells were plated in BioCoat Matrigel
invasion chambers (BD Biosciences, San Jose, CA) at a cell
density of 3 × 104 per chamber in RPMI 1640 supple-
mented with 5% fetal bovine serum (inner chamber) 48
hrs post-transfection. Self-supplied fibroblast conditioned
medium was used as chemoattractant in the outer cham-
ber. The conditioned medium was obtained from fibrob-
lasts isolated as described by Costea et al[18] cultivated in
DMEM supplemented with 10% fetal bovine serum. The
medium was collected when the cells were 70% confluent.
After 48 hrs incubation at 37°C and 5% CO2, non-invad-
ing cells remaining on the top surface of the chamber were
removed by scrubbing with a cotton-tipped swab, and the
invading cells that had adhered to the bottom surface of
the chamber membranes were fixed, stained with hema-
toxylin and counted.
Clinical melanoma specimens
Formalin-fixed, paraffin-embedded tissue from 149 pri-
mary and 68 metastatic melanomas, as well as 11 benign
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nevi, was examined for expression of FABP7 protein. Of
the primary tumors, 93 were classified as superficial
spreading (SSM) and 56 as nodular melanomas (NM).
Clinical follow-up was available for all patients. The study
was approved by the Regional Committee for Medical
Research Ethics in Norway.
Immunohistochemical analysis
Sections of formalin-fixed, paraffin-embedded tissue were
immunostained using the two-step EnVision system
(DAKO EnVision™, DAKO A/S). Deparafinized sections
were microwaved in low pH buffer (pH 6.0) (DAKO) at
750 W for 5 minutes and then at 500 W for 15 minutes to
unmask the epitopes. After treatment with 1% hydrogen
peroxide for 5 minutes to block endogenous peroxidase,
the sections were incubated with polyclonal rabbit anti-
human FABP7 antibody (R&D Systems) for 30 minutes at
room temperature followed by 30 minutes incubation
with mouse anti-goat antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). The sections were then incubated
with HRP-labeled secondary antibody for 30 minutes fol-
lowed by 5 minutes incubation at RT with DAB substrate
(DAKO A/S). All series included positive controls. Four
semiquantitative classes were used to describe the number
of stained cells: negative,  5%, 6–50% and >50%. Both
nuclear and cytoplasmic staining was scored. Staining was
evaluated by a surgical pathologist (BD). A subset of the
cases (n = 50) was additionally scored by another author
(AS).
Statistical analysis
Statistical analysis was performed using the SPSS program
version 13.0 (Chicago, IL). The differences between
FABP7 expression in benign nevi, primary melanomas
and metastases were analyzed using the Chi-square test.
The relationship between FABP7 expression and mean
tumor thickness was evaluated nonparametrically using
the Mann-Whitney two sample test. The association
between expression of FABP7 and cell cycle markers was
performed using the Fischer's exact test. Kaplan-Meyer
estimates and the log-rank test were used for survival anal-
ysis. P < 0.05 was considered statistically significant.
Results
Identification of molecules involved in survival of 
melanoma cells as multicellular aggregates in suspension 
using gene expression profiling
We previously showed that PMA treatment protects
melanoma cells from suspension-mediated apoptosis
while the MEK1 inhibitor PD98059 has the opposite
effect [2]. In order to identify new factors involved in
anchorage-independent growth of melanoma cells, we
compared mRNA expression profiles from the melanoma
cell line WM35, cultured in monolayer or as untreated
spheroids, as well as following treatment of the spheroids
with PMA and/or PD98059 for 24 hours.
The FABP7 gene was among the genes showing the highest
differential expression. While no notable difference was
observed between monolayer cells and spheroids, treat-
ment with PMA or PD98059, as well as with PD98059
and PMA in combination, led to FABP7 mRNA down-reg-
ulation in treated spheroids compared to the spheroid
control (Figure 1a). The microarray results were validated
using real time RT-PCR (Figure 1b).
FABP7 is expressed in melanoma cell lines and regulated 
through PKC and the MAPK/ERK1/2 signaling pathway
The protein level of FABP7 in monolayer culture,
untreated spheroids and spheroids treated with PMA and/
or PD98059 for 24 hrs was analyzed using western blot.
As shown in Figure 1c, no change in FABP7 protein level
was observed between monolayer cells and untreated
spheroids while in spheroids treated with PMA and/or
PD98059, the protein level was reduced compared to con-
trols. This was in accordance with the reduction of FABP7
mRNA levels. A similar reduction in FABP7 protein level
was obtained in monolayer cultures treated with PMA
and/or PD98059 (data not shown).
In order to reveal if FABP7 expression levels differ during
the cultivation of the WM35 cells following PMA and/or
PD98059 treatment, we performed a time course study.
The monolayer cells were treated with PMA or PD98059
from 0,5 hrs to 72 hrs. As shown in Figure 2. we observed
down-regulation of FABP7 protein after 12 hrs in both
PMA and PD98059 treated cells although the effect of
PMA was more pronounced over time. The down-regula-
tion was sustained for up to 72 hrs for both treatments.
These results were supported by real time RT-PCR (data
not shown).
To examine if FABP7 is frequently expressed in melanoma
cell lines we analyzed the level of FABP7 mRNA and pro-
tein in two primary (WM1341 and WM902B) and seven
metastatic cell lines (WM239, WM45.1, WM983, WM9,
LOX, MeWo and FEMX-I) in addition to WM35. As shown
in Figure 3a and 3b, variable levels of FABP7 mRNA and
protein were detected in 9 out of 10 cell lines. With the
exception of WM45.1, good concordance between mRNA
and protein levels was observed in all the cell lines. No
clear differences were observed between FABP7 expression
levels in cell lines originating from primary tumor vs.
metastasis.
FABP7 is involved in proliferation and invasion of 
melanoma cells
In order to further investigate the function of FABP7 we
chose to transiently down-regulate FABP7 using specific
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A) The expression level of FABP7 as detected by Affymetrix microarray analysis in WM35 cells grown as spheroids for 24 hrs with or without PMA and/or PD98059 compared to untreated m nol er controlFigur 1
A) The expression level of FABP7 as detected by Affymetrix microarray analysis in WM35 cells grown as sphe-
roids for 24 hrs with or without PMA and/or PD98059 compared to untreated monolayer control. B) FABP7 
mRNA expression levels in the same cells as in (A) measured by real time RT-PCR. The results presented are relative to 
untreated monolayer control. The average was calculated from three independent experiments and presented with standard 
deviation. C) Expression of the FABP7 protein by Western blot analysis. Down-regulation of FABP7 mRNA and protein was 
seen after treatment with PMA and PD98059 for 24 hrs. -tubulin was used as loading control.
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siRNA in the WM35 and WM239 cell lines, which we
found to have high FABP7 expression. The effect of down-
regulation on proliferation, invasion and apoptosis was
examined. Monolayer cells were incubated for 48 hrs with
FABP7 siRNA or a control siRNA and analyzed for trans-
fection efficiency by western blot (Figure 4a). As demon-
strated in figure 4b and 4c, FABP7 down-regulation
reduced proliferation by 29% in WM35 and 84% in
WM239 cells as compared to scrambled siRNA control
transfected cells. Similar results were obtained when the
cells were grown in suspension (data not shown).
The degree of apoptosis was assessed using TdT-mediated
dUTP nick end labeling (TUNEL) staining and flow
cytometry. Analysis of both monolayer and spheroid cul-
tures showed that down-regulation of FABP7 did not
affect the percentage of apoptotic cells (data not shown).
Together these results suggest that FABP7 is most likely
involved in proliferation and not apoptosis in melanoma
cells.
We investigated the effect of FABP7 down-regulation on
invasion using the Matrigel assay. The number of invading
cells was reduced by 55% and 40% in WM35 and WM239
cell respectively after transfection with FABP7 siRNA com-
pared with scrambled siRNA control-transfected cells (Fig-
ure 4d), suggesting that FABP7 contributes to the
invasiveness of melanoma cells.
FABP7 is expressed in melanomas and associated with 
tumor thickness
In order to examine the clinical relevance of FABP7, paraf-
fin-embedded tissue from a panel of benign nevi and pri-
mary and metastatic melanomas was analyzed for
expression of FABP7 protein using immunohistochemis-
try. Heterogeneous cytoplasmic and/or nuclear expression
of FABP7 was observed in 91% of the nevi, 71% of the pri-
mary tumors and 70% of the metastases. The results are
summarized in Table 1 and 2 and illustrated in Figure 5.
Statistical analysis demonstrated a significant higher cyto-
plasmic FABP7 expression in nevi compared to primary
and metastatic melanomas (P = 0.023), with comparable
nuclear expression. A two-tier analysis of primary and
metastatic melanomas showed comparable expression for
both cytoplasmic and nuclear expression (P > 0.05). Good
concordance (>80%) was achieved between the two
observers. Discrepant cases were resolved through a con-
sensus session.
Since 62% (92/149) of the primary tumors expressed
cytoplasmic FABP7 in more than 5% of the cells, this cut-
off was used to distinguish between high and low protein
levels. Applying the same cutoff when evaluating nuclear
staining, we observed that only 13% (19/149) of the
tumors had high protein expression levels. Higher cyto-
plasmic FABP7 was significantly associated with increased
thickness of SSM (P = 0.021). In addition, in this group of
patients, a trend towards increased relapse-free survival (P
= 0.069) for patients whose tumors expressed less FABP7
was observed. No such correlation was observed in NM
(Table 3 and Figure 6). We did not observe any significant
correlation between FABP7 staining and overall survival
for patients diagnosed with either SSM or NM (data not
shown). Nuclear staining had no association with disease
outcome (data not shown).
Relationship between FABP7 expression and markers of 
proliferation
Since our panel of primary and metastatic melanomas has
previously been analyzed for expression of cell cycle pro-
gression markers [19-21] and activation status of MAPK/
ERK1/2 [22], it was of interest to examine the relationship
between FABP7 expression and the levels of these factors.
The results showed no correlation between cytoplasmic
FABP7 expression and the expression of the cyclins A, D1
or D3 or the cdk inhibitors p21CIP1/WAF1and p27Kip1 in
either SSM or NM. However, a trend for an association
between cytoplasmic FABP7 and Ki-67 (P= 0.07) in SSM
was observed, which is in support of our in vitro results,
suggesting FABP7 involvement in proliferation. Further-
more, expression of activated MAPK/ERK1/2 did not cor-
Western blot showing the expression of the FABP7 protein in WM35 monolayer cells treated with PMA or PD98059 for 0.5 hrs, 4 hrs, 12 hrs, 24 hrs, 48 hrs and 72 hrsFigu e 2
Western blot showing the expression of the FABP7 
protein in WM35 monolayer cells treated with PMA 
or PD98059 for 0.5 hrs, 4 hrs, 12 hrs, 24 hrs, 48 hrs 
and 72 hrs. -tubulin was used as loading control.
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relate with FABP7 expression. Interestingly, however, we
observed that if the cutoff level was changed (only total
lack of FABP7 was regarded as low expression), MAPK/
ERK1/2 expression did positively correlate with cytoplas-
mic FABP7 expression in SSM (P= 0.047). This was not the
case for NM, regardless of cutoff. Nuclear expression of
FABP7 did not correlate with any of the examined markers
(data not shown).
A) FABP7 mRNA level in melanoma cell lines as measured by real time RT-PCR analysisFigure 3
A) FABP7 mRNA level in melanoma cell lines as measured by real time RT-PCR analysis. Three primary and 7 
metastatic melanoma cell lines were evaluated. The expression levels are shown relative to the WM35 cell line. B) Expression 
of FABP7 protein by western blotting, with -tubulin as loading control.
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A) Western blot analysis showing down-regulation of FABP7 in WM35 and WM239 cells after transfection with FABP7 siRNA, with -tubulin as lo ding controlFigur  4
A) Western blot analysis showing down-regulation of FABP7 in WM35 and WM239 cells after transfection 
with FABP7 siRNA, with -tubulin as loading control.B-C) The effect of FABP7 down-regulation on proliferation in 
WM35 (B)and WM239 (C)cells measured by [3H]Thymidine incorporation 72 hrs post transfection. Down-regulation of 
FABP7 protein using siRNA led to reduction of DNA synthesis, suggesting reduced proliferation in both cell lines.D) Matrigel 
invasion assay. Inhibition of invasion ability of WM35 and WM239 cells following FABP7 down-regulation with siRNA. The 
average was calculated from three independent experiments and presented with standard deviation.
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Discussion
We previously showed that PMA-mediated PKC activation
and activation of the MAPK/ERK1/2 pathway contributes
to increased proliferation and reduced apoptosis of
melanoma cells under anchorage-deprived conditions. In
the present study we used gene expression profiling to
identify additional genes involved in these processes, and
found the FABP7 gene to be differentially expressed and
down-regulated in WM35 spheroids following both PKC
activation and MEK1 inhibition while no differences were
observed between monolayer cells and untreated sphe-
roids. PKC activation and MAPK/ERK1/2 down-regula-
tion had opposite effect on anchorage-independent
survival of the melanoma cells, but both negatively regu-
lated FABP7. This observation argues against FABP7
involvement in promotion of anchorage-independent
survival in these cells. Thus, it is likely that these pathways
are regulating additional factors important for survival,
independent of FABP7 down-regulation.
PKC is a well known activator of the MAPK/ERK1/2 path-
way [23,24] and we have previously reported that PMA
activates MAPK/ERK1/2 independently of its upstream
activator MEK1 [2]. Since PMA treatment down-regulates
FABP7 even in the presence of activated ERK1/2 this
down-regulation is likely to be PMA/PKC-mediated but
MAPK/ERK1/2-independent. Together this suggests that
FABP7 can be regulated by both signaling pathways inde-
pendently in melanoma cells. Several reports have shown
that activation of the MAPK/ERK1/2 pathway can induce
increased activity of peroxisome proliferator-activated
receptors / (PPAR /). Similarly, PKC can both posi-
tively and negatively regulate PPAR-dependent tran-
scription [25-27]. Binding of PPAR to its response
element, PPRE, has been shown to up-regulate FABP1 and
FABP4 [5,28,29]. It is reasonable, therefore, to assume
that FABP7 might also be regulated through this mecha-
nism.
To further clarify the role of FABP7 in melanomas we used
siRNA to down-regulate its expression in the primary
WM35 and metastatic WM239 melanoma cell lines. This
down-regulation notably inhibited proliferation in both
cell lines, but did not affect the degree of apoptosis, argu-
ing for involvement of FABP7 in melanoma proliferation.
In support of our results, Goto et al [12] showed that pro-
liferation of melanoma cell lines is reduced upon down-
regulation of FABP7, also without affecting apoptosis.
Our results showed that down-regulation of FABP7 nega-
tively influences the invasive potential of melanoma cells,
also in agreement with Goto et al [12] who demonstrated
that down-regulation of FABP7 decreased invasiveness in
2 of 6 melanoma cell lines. In further support of this
hypothesis are the data of Mita et al., who showed that
FABP7 increases the invasion properties of astrocytoma
cells [30]. Of note, when FABP7 was reintroduced in the
metastatic cell line LOX, lacking constitutive FABP7
expression, no effect on apoptosis, proliferation or inva-
sion was observed (preliminary results, data not shown).
Similar results were reported by Goto et al. [12] in 4 out of
6 melanoma cell lines. However, the reason for the dis-
crepancy between the cell lines is still unclear. Thus, the
biological role and detailed functional mechanism of the
FABP7 protein in melanoma cells remains to be further
investigated.
Table 2: Number (percentage) of melanocytic lesions expressing different levels of FABP7
Tumor type No. of tumors Cytoplasm Nucleus
-  5% 6–50% > 50% -  5% 6–50% > 50%
Benign nevi 11 1 (9) 0 (-) 1 (9) 9 (82) 3 (28) 4 (36) 4 (36) 0 (-)
Primary melanomas 149 43 (28) 14 (9) 42 (28) 50 (34) 79 (53) 51 (34) 16 (11) 3 (2)
SSM 93 32 (34) 10 (11) 25 (27) 26 (28) 51 (55) 31 (33) 9 (10) 2 (2)
NM 56 11 (20) 4 (7) 17 (30) 24 (43) 28 (50) 20 (36) 7 (12) 1 (2)
Metastases 68 21 (31) 8 (11) 21 (31) 18 (27) 40 (59) 20 (29) 7 (11) 1 (1)
Table 1: Number (percentage) of melanocytic lesions expressing FABP7 in different cellular compartments
Tumor Type No. of tumors Total no. of positive Cytoplasm Nucleus Cytoplasm/nucleus
Benign nevi 11 10 (91) 2 (18) 0 (0) 8 (73)
Primary melanomas 149 106 (71) 36 (24) 0 (0) 70 (47)
SSM 93 61 (66) 19 (21) 0 (0) 42 (45)
NM 56 45 (80) 17 (30) 0 (0) 28 (50)
Metastases 68 48 (70) 20 (29) 1 (2) 27 (39)
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Immunohistochemical staining of FABP7 in a benign nevus (A) primary melanoma (B) and metastatic melanoma (C)Figure 5
Immunohistochemical staining of FABP7 in a benign nevus (A) primary melanoma (B) and metastatic 
melanoma (C).
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Several members of the FABP family have been reported
to be differentially expressed in cancer. Loss of expression
of FABP4 was reported in bladder cancer while FABP1 and
FABP2 are over-expressed in prostate and breast cancers
[7,31-33]. In accordance with Goto et al. [12] we found
that FABP7 is expressed in both primary and metastatic
melanoma cell lines, as well as in melanocytic lesions.
However, there were no clear differences in FABP7 expres-
sion levels in primary derived compared to metastatic
derived cell lines, suggesting that FABP7 is not associated
with tumor aggressiveness. On the other side, cell lines are
cultured in artificial environments that can not be directly
compared to tumors in vivo and a connection to tumor
aggressiveness and progression can not be completely
excluded. In support of this, analysis of the clinical data
showed that thicker SSM expressed higher levels of FABP7.
Furthermore, a trend between high levels of FABP7 and
reduced disease-free survival for these patients suggest
that FABP7 could contribute to disease progression, possi-
bly by increasing the invasion potential of the tumors. In
support of our results, a negative association between
FABP7 expression and survival was recently observed for
patients with glioblastoma [10,34]. We also observed a
positive trend between FABP7 and the proliferation
Table 3: Relationship between cytoplasmic FABP7 expression and tumor thickness in primary melanomas
Tumor type Expression No of patients Average depth of growth (mm) P
SSM Negative* 41 1.59
Positive 48 2.17 0.021
NM Negative* 15 4.32
Positive 41 4.78 0.697
* Considered negative if < 5% tumor cells showed positive immunoreactivety of FABP7
Kaplan-Meier curve demonstrating a negative trend (P = 0.069) between protein expression of cytoplasmic FABP7 and relapse-free survival for patients with SSMFigure 6
Kaplan-Meier curve demonstrating a negative trend (P = 0.069) between protein expression of cytoplasmic 
FABP7 and relapse-free survival for patients with SSM. FABP7 expression was considered high when > 5% of the 
tumor cells showed positive staining with the anti-FABP7 antibody.
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marker Ki-67 in SSM, suggesting that FABP7 may contrib-
ute to increased proliferation in vivo. Since the patient sub-
groups in the analyses were small, the suggested clinical
significance of FABP7 expression remains to be confirmed
in larger patient cohorts.
In the clinical specimens, FABP7 protein expression was
highest in nevi, with no observed differences between pri-
mary and metastatic melanoma. This is in accordance
with the study by de Wit et al. [11] who reported that
FABP7 is down-regulated in melanoma tissue compared
to nevi using oligonucleotide arrays. The higher expres-
sion of FABP7 in nevi compared to melanomas seems
contradictory to the in vitro data in the present study, as
well as to the association with clinical parameters of dis-
ease progression. We are unable to explain this discrep-
ancy at present. However, the majority of benign nevi are
terminal lesions that do not progress to melanoma and
the molecular events regulating these processes might dif-
fer. It is also possible that different expression levels of
FABP7 mediate different effects during disease progres-
sion.
Variation in sub-cellular localization of FABP7 has been
reported in developing radial glia cells, glioma cell lines
[9,35] and glioblastoma multiforme (GBM) specimens
[34]. Since FABP proteins are considered to be co-activa-
tors in PPAR-mediated gene transcription control, this
could in part explain FABP7 translocation to the nucleus
(reviewed in [5]). Recently, it was reported that nuclear
expression of FABP7 is restricted to infiltrative tumor
types and related to EGFR amplification and over-expres-
sion as well as poor prognosis of GBM [10,34]. In our
melanoma cohort we did not find any association
between nuclear expression of FABP7 and disease-free or
overall survival.
Conclusion
We confirmed that FABP7 protein is expressed in melano-
cytic lesions and showed that it can regulate proliferation
and invasion in melanoma cells in vitro. Our results fur-
ther suggest that FABP7 can be regulated by PKC and the
MAPK/ERK1/2 pathway through independent mecha-
nisms. In addition, FABP7 expression is associated with
proliferation and tumor thickness in the patients with
SSM, suggesting that for these patients FABP7 could be a
potential target for therapy.
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APPENDIX

ABBREVATIONS
Akt  V-Akt murine thymoma viral oncogene homolog 
AP1  Activator protein 1 
APAF-1 Apoptosis protease activationg factor-1 
ARF  Alternative reading frame of the INK4 locus 
ATF1/2            Activating transcription factor 1 or 2 
Bad                  Bcl-2-associated death promoter homolog 
Bak  Bcl-2 antagonist/killer 
Bax  Bcl-2-associated X protein 
Bcl-2  B-cell chromic lymphocytic leukemia/lymphoma-2 protein 
Bid  BH3 interacting domain death agonist 
Bim  Bcl-2 like 11 protein 
Bcl-XS/XL           Bcl-2 like1 protein (short form/long form) 
B-RAF V-raf murine sarcoma viral oncogene homolog B1 
cAMP  Cyclic adenosine monophosphate 
CDK  Cyclin dependent kinase 
CDKI  Cyclin dependent kinase inhibitor 
CDKN2A Cyclin dependent kinase inhibitor 2A 
c-fos  Cellular fos proto-oncogene 
c-jun  Cellular jun proto-oncogene 
c-myc  Cellular myc proto-oncogene 
CREB  cAMP responsive element binding protein 
DISC  Death-inducing signal complex 
DNA  Deoxyribonucleic acid 
E2F  E2F transcription factor 
ECM  Extracellular matrix 
EGF   Epidermal growth factor  
EGR1  Early growth response 1 
EGFR   Epidermal growth factor receptor 
Elk1  ELK1, member of ETS oncogene family 
ERK  Extracellular signal-regulated kinases  
Ets1  v-ets erythroblastosis virus E26 oncogene homolog 1 
 
FABP  Fatty acid binding protein 
FAK  Focal adhesion kinase 
FADD  Fas-associated death domain protein 
Fas  TNF receptor superfamily, member 6 
FasL  Fas lignad 
FGFR   Fibroblast growth factor receptor 
GSK3- Glycogen synthase kinase-3 beta 
IAP  Inhibitor of apoptosis 
ICAT  Beta-catenin-interacting protein 
IGF-1               Insulin-like growth factor-1 
IGF-1R            Insulin-like growth factor-1 receptor 
IGFBP             Insulin-like growth factor binding protein 
IL-1                 Interleukin-1 
ILK  Integrin-linked kinase 
INK4  Inhibitor of cyclin dependent kinase 4 
IRS                  Insulin receptor substrate 
JNK  c-jun N-terminal kinase 
kDa  kilo Dalton 
KIT  v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
LEF1  Lymphoid enhancer binding factor-1 
MAPK  Mitogen activated protein kinase 
Mcl-1  Myeloid cell leukemia sequence 1 
MDM2 Mouse double minute 2 
MEF2A Myocyte enhancer factor 2A 
MITF  Microphtalmia-associated transcriptional factor 
MMP  Matrix metalloproteinase 
MK2                MAPK-activated kinase 2 
MNK1/2 MAPK interacting serine/threonine kinase 1 and 2 
MSK1             Mitogen-and stress-activated protein kinase 1 
mRNA  Messenger ribonucleic acid 
mTOR  Mammalian target of rapamycin 
NFAT4 Nuclear factor of activated T-cells 4 
NF-B  Nuclear factor kappa-B 
NGF  Nerve growth factor 
 
NR4a1             Nuclear receptor subfamily 4, group A, member 1 
H-RAS Human homolog to Harvey rat viral sarcoma oncogene, encoding RAS 
N-RAS Neuroblastoma RAS viral (v-ras) oncogene homolog 
PDGFR  Platelet-derived growth factor receptor  
PDK1 and 2 Phosphoinositide–(3,4,5)-triphosphate-dependent-kinases 1and 2 
PI3K  Phosphoinositide 3 kinase 
PIP2  Phosphatidylinositol-4,5-bisphosphate 
PIP3  Phosphatidylinositol-3,4,5-trisphosphate 
PKC  Protein kinase C 
PLA2  Phospholipase A2 
PMA  Phorbol-12-myristate-13-acetate 
PP2  4-Amino-5-(4-chlorphenyl)-7-(t-butyl)(3,4-d) pyrimidine 
PPAR  Peroxisome proliferators-activated receptor 
PTEN  Phosphatase and tensin homolog deleted from chromosome 10 
RACK1 Receptor for activated kinase C 1 
RB  Retionoblastoma 
RTK  Receptor tyrosine kinase 
RGF  Radial growth phase 
RXR                Retinoid X receptor 
SA--GAL Senescence associated acidic -galactosidase 
Sap-1a  Serum response factor (SRF) associated protein 1 
Shc  Src homology 2 domain containing 
siRNA  Small interfering RNA 
Smac/Diablo Second mitochondria-derived activator of caspases/Direct IAP-binding protein 
SMAD4 Mothers against decapentaplegic homolog 4 
Src  Human homolog to the avian v-Src gene of the Rous Sarcoma virus 
STAT1/3 Signal transducer and activator of transcription 1 and 3 
Tau  Microtubule-associated protein Tau 
TGF-  /ß Transforming growth factor-alpha/beta  
TNF-             Tumor necrosis factor-alpha 
TPA  12-O-tetradecanoyl phorbol 13-acetate 
TRAIL TNF-related apoptosis-inducing ligand 
TUNEL Terminal deoxynucleotidyl transferase end labeling 
UV  Ultra violet 
 
VEGFR  Vascular endothelian growth factor receptor 
VGF  Vertical growth phase 
Wnt  Wingless-type MMTV integration site family 
 
 
